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ABSTRACT
The self-assembly of multiple protein subunits via noncovalent interactions provides 
a diverse collection of nanoarchitectures. Polyhedral capsids represent a particularly 
interesting type of structure in which the protein forms a closed three-dimensional surface 
that can function as a molecular container. Understanding capsid self-assembly could 
benefit further development of nanomaterials for many applications, such as drug 
delivery and biocatalysis. In this thesis, Aquifex aeolicus lumazine synthase (AaLS) is 
used as a model for investigating capsid self-assembly. The 60-subunit capsids formed 
by AaLS in vivo can be viewed as dodecamers-of-pentamers. Currently, methods are 
lacking for controlling AaLS assembly in vitro, which imposes important limitations on 
cargo loading. Interestingly, the diverse quaternary structures in the lumazine synthase 
family, which includes capsids and pentamers, imply the possibility of exchanging 
assembly states in vitro. To better understand AaLS capsid assembly, the dodecahedral 
capsid was converted to pentamers via a strategy involving rational design and site- 
directed mutagenesis. Biophysical characterizations confirm that simultaneous 
substitution of three interfacial residues can yield stable pentamers. A pentameric AaLS 
variant that possesses a unique, strategically placed cysteine residue was engineered to 
enable capsid formation in vitro. This cysteine was modified with a thiophenol group by 
sequential thiol-disulfide exchange reactions. The increase in nonpolar surface area upon
modification of this cysteine allows for assembly of the pentamers into capsids that 
resemble wild-type AaLS, presumably by recapitulating hydrophobic interactions present 
at the pentamer-pentamer interface. In an alternative approach, a pH-dependent switch 
for AaLS capsid disassembly was developed. For this switch, the ability to change 
assembly state relies on the presence of three engineered histidine residues per subunit, 
located near the three-fold symmetric interface of the capsid. These histidines minimally 
interfere with the capsid structure at high pH where their side chains are neutral. 
However, at lower pH, histidine protonation can trigger the dissociation of the capsid into 
pentamers, presumably due to charge repulsion. Further, this switch is reversible, as 60- 
subunit capsids can reform upon raising the pH. These studies of interconverting AaLS 
quaternary structures open the door to the development of improved encapsulation 
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1.1.1. How Does Protein Oligomerization Arise?
Proteins often form oligomers from the association of multiple polypeptide subunits.1,2 
Indeed, a survey of protein oligomeric states in Escherichia coli reveals that 
approximately 75% of the proteins are oligomers, predominantly homooligomers (~79 % 
of the oligomeric proteins in E. coli)1 Oligomeric proteins are essential elements for 
building many large architectures, such as cytoskeletal frameworks or protein capsids, 
which play important roles in many biological functions. In addition, proteins that form 
large architectures can also benefit from higher stability against degradation and 
denaturation.3 Interestingly, although many biological functions demand large structures, 
natural evolution has usually selected noncovalent symmetric assemblies of small or 
medium sized protein subunits to build large architectures rather than long single 
polypeptide chains.
Several evolutionary advantages have been proposed for building large structure from 
repeating small subunits.1 First, only minimal genome space is required for encoding a 
small subunit of a large assembly, which increases the coding efficiency compared to 
encoding a large polypeptide.4 In addition, producing long peptide chains could increase 
the risks of translation errors during protein synthesis.5,6 Further, building a large 
structure from many small subunits can decrease the biosynthetic cost required to fix 
translation errors because longer polypeptides are more expensive to discard and 
resynthesize than shorter ones.
Oligomeric proteins predominantly form symmetric structures by using identical 
subunits.1,7-9 To explain the great abundance of symmetric homooligomers occurring in
Nature, many advantages linked to symmetrical association have been proposed.1,10 
Theoretical analyses from thermodynamic considerations of oligomeric protein 
assemblies reveal that symmetrical associations are more energetically favorable 
compared to asymmetrical associations.11,12 Additionally, an interface between subunits 
in a homooligomeric protein can offer new amino acid arrangements to facilitate the 
formation of a new active site.13 Indeed, in evolution, forming an active site between 
subunits by reorganizing protein interfaces can be easier than generating a new active site 
within a single polypeptide by altering protein folding.10 Further, oligomeric proteins also 
offer excellent opportunities for allosteric regulation.14,15 Cooperative conformational 
changes between subunits in an oligomer allows efficient transfer of information from 
one subunit to the next or to all of the other subunits in a protein.16
1.1.2. Interfaces and Hotspots 
Protein-protein interfaces govern many of the assembling and folding behaviors of 
oligomeric protein complexes.17 When two or more protein monomers come into contact 
and several weak, noncovalent interactions occur among the amino acids at the surface 
of each monomer. Extensive studies of many protein-protein interfaces have revealed that 
these protein-protein interfaces recognize their binding partners with high specificity 
according to the complementarity of shape and chemical properties, such as forming 
hydrophobic patches, hydrogen bonds, or salt bridges.16,18 Based on the shape and the 
chemical properties, interfaces of oligomeric proteins might be sorted into two categories: 
interfaces of obligate complexes and interfaces of nonobligate complexes.19 However, 
some protein interfaces are hard to categorize clearly because oligomerization states often
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depend on the conditions and environment.20 21
Three types of interactions (hydrophobic interaction, hydrogen bonding, and 
electrostatic interaction) are commonly found to be important in stabilizing protein- 
protein interfaces. Hydrophobic interactions often make large contributions to the 
stabilization of oligomeric protein interfaces.22,23 When nonpolar amino acids interact 
with each other via van der Waals contacts in an aqueous environment, the exclusion of 
ordered water molecules from the contact area to the bulk solution provides a strong 
energetic driving force for association. Typically, protein-protein interfaces comprise a 
greater fraction of hydrophobic residues compared to noninterfacial protein surfaces. 
However, protein-protein interfaces also contain a fairly large amount of polar and 
hydrophilic residues and are therefore less hydrophobic than protein cores.13 These polar 
groups form electrostatic and hydrogen bonding interactions that may also contribute to 
interface stability. Further, the specificity of protein association is largely determined by 
the complementary nature of electrostatic interactions and the geometric requirements of 
hydrogen bonding.22 Indeed, on average, the number of hydrogen bonds is proportional 
to the interface area, occurring with a frequency of about one hydrogen bond per 200 A2 
of protein interface surface area.23,24 Additionally, interfaces can sometimes incorporate 
disulfide linkages or metal binding sites to gain extra stability.
Binding energies are not distributed evenly at protein interfaces. A group of a few 
residues that contribute a disproportionately large amount of the binding energy at 
intermolecular protein interfaces are called “hot spots.”25 Hot spots are usually clustered 
in interfaces that are highly complementary both in shape and amino acid arrangement. 
Although there is not a preference at hot spots for a single type of amino acid, such as
4
5hydrophobic or charged residues, a systematic analysis of hot spots reveals a nonrandom 
amino acid composition; three amino acids (arginine, tryptophan, and tyrosine) are found 
to appear the most frequently at hot spots.26 Tryptophan and tyrosine have bulky aromatic 
side chains, which can contribute to aromatic n-interactions, serve as hydrogen bonding 
partners and provide a large hydrophobic surface. Arginine is also capable of forming 
multiple types of favorable interactions, such as participating in up to five hydrogen 
bonds and forming a salt-bridge using its positively charged guanidino group. Isoleucine, 
histidine, and aspartic acid are also quite common in hot spots. Interestingly, compared 
to isoleucine, leucine is rarely found in hot spots even though they are constitutional 
isomers with identical chemical properties. Serine, threonine, and valine residues are also 
extremely rare at hot spots.27
Studying protein-protein interactions at the atomic level is crucial for understanding 
the biological functions and structures of proteins. It not only allows an extensive 
understanding of the chemistry of protein-protein interactions, it also can provide insight 
into protein self-assembly. The identification of important hot spot residues at protein- 
protein interfaces benefits many important applications, including rational drug design, 
analysis of metabolic and signal transduction pathways, and development of novel protein 
nanomaterials.
1.1.3. Hierarchical Assembly of Proteins
Numerous nanoscale architectures can be constructed from self-assembly of multiple 
protein building blocks.2,28,29 For example, filamentous structures, such as amyloid-like 
fibrils and actin fibrils, can be obtained by assembling protein subunits linearly.30 Such
linear assemblies can be made by two different types of subunit arrangements. In the first 
type, building blocks are assembled with the same direction relative to the filament axis 
and connected head-to-tail. In the second type, building blocks meet in a head-to-head 
and tail-to-tail assembly with two-fold rotational symmetry.
In addition to linear assemblies, polyhedral structures, such as viral capsids, can also 
be constructed by protein self-assembly.31 Polyhedral capsids are assembled from 
multiple subunits in a highly symmetric fashion. Cubic symmetries have been proposed 
to be required for building an isomeric capsid that allows close packing of repeating 
subunits.2 Three types of cubic symmetries, including tetrahedral (containing six two-fold 
axes and four three-fold axes), octahedral (containing 12 two-fold axes, eight three-fold 
axes, and six four-fold axes), and icosahedral (containing 30 two-fold axes, 20 three-fold 
axes, and 12 five-fold axes), are capable of generating capsids.
The hollow inner space of polyhedral capsids can be used to sequester guest 
molecules. Such encapsulation ability is used by viruses to protect their genomes. Some 
multi-enzyme complexes form cage-like structures that can be used to regulate enzyme 
activities by limiting the entry or exit of potential substrates.32-34 In addition, by 
encapsulating a group of enzymes involved in a reaction cascade, the overall catalytic 
efficiency can be enhanced via substrate channeling.35
1.2. Polyhedral Capsids
1.2.1. Icosahedral Viral Capsids 
Viruses construct protein shells that enclose their genomes to prevent damage or 
degradation. Many viral capsid shells are formed by arranging repeating subunits into
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icosahedral symmetry. This strategy allows viruses to build a given size protein capsid 
shell economically by using only one or a few different types of subunits, which helps 
minimize genome size.4
Icosahedral symmetry requires 60 identical units with equivalent contacts between 
each of them. However, most icosahedral viral capsids are larger than a capsid that can 
be built by 60 identical subunits. To explain this observation, the rule of quasi equivalence 
and the lattice triangulation number T was introduced.31 An icosahedron can be built from 
hexamers and pentamers constructed from more than 60 identical subunits, but are only 
quasi-symmetric, which means that the identical subunits are in different conformations 
and make different contacts with their neighbors in the icosahedron.
The facets of an icosahedron can been considered as 20 equilateral triangles, which 
can be further subdivided into smaller triangular subunits. This process is called 
triangulation.36,37 According to the concept of the quasi equivalence rule, triangulation 
generates hexavalent (six-fold) and pentavalent (five-fold) positions on the icosahedral 
lattice. The triangulation process can be expressed by the equation
T = h2 + hk + k2 (1.1)
In this equation, T is the triangulation number or the number of subunits in an icosahedral 
asymmetric unit. The vectors h and k correspond to the position of the five-fold vertex in 
the triangulated icosahedral lattice and they can be either zero or positive integers (Figure 
1.1).
Quasi symmetry allows filling multiple identical subunits into each of the 60
7
8Figure 1.1. Triangulated facets for icosahedra. The geometry of each facet is described 
by the hexagonal coordinate system. The facets contain equilateral triangles with an 
integral number of subunits. The T number of an icosahedron is determined by the h and 
k vectors from the origin (O) and the equation, T = h2 + hk + k2. The facets of T = 1 (h = 
1, k = 0), T = 3 (h = 1, k = 1), and T = 4 (h = 2, k = 0) icosahedron are shown as cyan, 
red, and green triangles, respectively.
symmetrically identical positions in the icosahedron (Figure 1.2). Consequently, the size 
of the 20 equilateral triangles and the icosahedral particle increase proportionally to the 
T number (under the assumption that the size of subunits stays constant). An icosahedral 
capsid with a given T number will consist of 60T subunits arranged into 12 pentamers 
with 10(T -  1) hexamers (Figure 1.3).
The spontaneous formation of capsid particles from multiple protein subunits is a 
sophisticated thermodynamic process driven by many weak protein-protein 
interactions.38 Such an assembly process is similar to the classical nucleation theory of 
polymerization reactions for macromolecular polymers.39,40 In this theory, assembly of a 
polymer is initiated by a nucleation event followed by an elongation step involving a 
cascade of faster reactions that add subunits into the polymer at stable rates until 
equilibrium between the polymer and the free subunits is reached. At the equilibrium 
stage, subunits can freely associate and disassociate from this open-ended polymer. A 
concentration (referred to as the critical concentration) of free subunits in solution at this 
stage must be present to maintain the polymer as a unique phase.
The overall assembly process of an icosahedral capsid exhibits sigmoidal kinetics.38 
There is a lag phase early in the assembly reaction, resulting from the slow formation of 
nuclei, followed by a rapid assembly of subunits and ending with a steady-state when the 
critical concentration of free subunits has been achieved.41 The assembly pattern of an 
icosahedral capsid is similar to a classic polymer but with different kinetic and 
thermodynamic meanings. Icosahedral capsids assemble into a closed lattice with a 
defined number of subunits instead of an open-end polymer with an indefinite number of 
subunits. Further, in contrast to a classic polymer, in which the lag phase represents the
9
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Figure 1.2. Models for T = 1, T = 3, and T = 4 icosahedral capsids. Quasi symmetry is 
shown for the T = 3 and T = 4 icosahedrons. Subunits in each asymmetric unit are colored 
differently. (A) The T = 1 icosahedral capsid consists of 12 pentameric building blocks 
for a total of 60 protein subunits. (B) The T = 3 icosahedral capsid consists of 12 
pentameric and 20 hexameric building blocks for a total of 180 protein subunits. (C) The 
T = 4 icosahedral capsid consists of 12 pentameric and 30 hexameric building blocks for 
a total of 240 protein subunits.
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T=1 T=3
Figure 1.3. Examples of virus capsids with different T numbers. The asymmetric units 
of each capsid is shown in black squares; each subunit within an asymmetric unit is 
colored differently. The capsid structural models were generated using Chimera and the 
crystal structural information downloaded from RCSB protein data bank (www.pdb.org). 
The PDB id for satelite tobacco necrosis virus is 3s4g. The PDB id for cowpea chlorotic 
motte virus is 1cwp. The PDB id for human hepatitis B virus is 1qgt.
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formation of a single nucleus, the lag phase of icosahedral capsid assembly corresponds 
to the generation of many individual nuclei. Each of these nuclei can go on to form 
sequentially larger and more complete intermediates. Complete capsids are then formed 
until the free subunit concentration reaches the pseudocritical concentration.38
1.2.2. Nonviral Protein Capsids
In addition to viral capsids, some nonviral proteins are also found to form polyhedral 
capsids in Nature. Many nonviral capsids form a reaction chamber by incorporating 
reactive molecules, such as enzymes, into their inner cavities. In some cases, proteins that 
form capsids can also function as catalysts, serving as an active participant in a multi­
enzyme complex that carries out a reaction cascade. The compartmentalization of 
enzymes can regulate catalytic activity by controlling access of substrates to the enzymes 
inside of the capsid. Further, the catalytic efficiency can be enhanced by increasing the 
local concentration of enzymes and intermediates formed during multi-enzyme reaction 
cascades via substrate channeling. Examples of nonviral capsids that form multi-enzyme 
complexes include pyruvate dehydrogenase, fungal fatty acid synthase, lumazine 
synthase-riboflavin synthase complex, and bacterial microcompartments.33,34,42-44
Pyruvate dehydrogenase consists of three enzymes: pyruvate decarboxylase (E1 
subunit), dihydrolipoyl acetyltransferase (E2 subunit), and dihydrolipoamide 
dehydrogenase (E3 subunit). The E2 subunits were found to self-assemble into 24-subunit 
octahedra (found in Gram-negative bacteria) or 60-subunit dodecahedral structures 
(found in eukaryotes and Gram-positive bacteria).45 The E1 and E3 subunits 
noncovalently bind to the surface of the E2 capsid core. This E1/E2/E3 complex catalyzes
13
a directed sequence of acetyl coenzyme A biosynthesis reactions.
Fungal fatty acid synthase forms a 2600 kDa a6P6 heterododecameric complex.34 The 
cage-like structure of fatty acid synthase complex contains three distinct units. A central 
catalytic disk, formed by six a chains, is sandwiched by two domes, formed by the P 
chains, generating one reaction chamber on each side of the center disk. Six catalytic 
domains, which catalyze the sequential reactions of fatty acid biosynthesis, were found 
in the properly folded a and P polypeptide chains.
The multi-enzyme complex formed by Bacillus subtilis lumazine synthase encloses 
another enzyme, riboflavin synthase, in the interior of a T = 1 dodecahedroal capsid.43 
Lumazine synthase and riboflavin synthase together catalyze the last two steps in the 
riboflavin biosynthesis pathway. Thus, the encapsulation contributes to a more efficient 
catalysis at low overall substrate concentration.46
Bacterial microcompartments provide another example of multi-enzyme reactors that 
act as protein-bounded organelles.44 The bacterial microcompartment capsid can enclose 
multiple types of enzymes, which catalyze a cascade of metabolic reactions, in the center 
of the capsids. There are several metabolic pathways carried out by different members of 
the bacterial microcompartment family.47 Depending on the pathway, the members in the 
bacterial microcompartment family contain different sets of enzymes.44 For example, the 
carboxysome, a polyhedral bacterial microcompartment that exists in most 
photosynthetic and chemoautotrophic bacteria, is involved in carbon fixation.44 The 
carboxysome capsid simultaneously encapsulates two enzymes, ribulose bisphosphate 
carboxylase-oxygenase (RubisCO) and carbonic anhydrase (CA). CA catalyzes the 
dehydration of bicarbonate, which can be utilized by RubisCO that is also available in the
carboxysome chamber. The colocalization of CA and RubisCO results in increased local 
concentration of these enzymes and facilitates channeling CO2 between them.48 In 
addition, the carboxysome capsid can also function as a transportation gate to trap the 
CO2 molecules inside of the capsid, providing a high local concentration of CO2 by 
preventing escape via diffusion to the bulk environment.47 As a result, the capsid forms 
an optimized environment for enhancing the efficiency of carbon fixation.
The capsids of bacterial microcompartments assemble from at least two different types 
of protein subunits into polyhedral structures with a size range of 80 to 200 nm.35 The 
polyhedral capsids of bacterial microcompartments are mainly built by hexameric 
building blocks.32 These hexagonal building blocks further self-assemble into tightly 
packed sheets, which form the flat facets of the polyhedral structure. A minor group of 
protein subunits found in the bacterial microcompartment capsids arrange into pentamers. 
Structural modeling and electron microscopy studies suggests that these pentamers form 
the vertices of the polyhedral structures.49
The tightly packed bacterial microcompartment capsid shell functions as an important 
diffusion barrier for controlling molecular transportation. Analysis of structural data led 
to the proposal that a narrow pore located at the center of each hexameric building block 
allows the transportation of small molecules into and out of the microcompartment.32 
Interestingly, an open form and a closed form have been observed for the pores in the 
hexameric building blocks.50 These two dramatically different conformations perhaps 
provide a gated transportation mechanism of molecules across the protein shell. Other 
bacterial microcompartments such as those involved in propanediol utilization (Pdu) and 
ethanolamine utilization (Eut) also form polyhedral structures similar to the carboxysome
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but they encapsulate different sets of enzymes involved in different metabolic 
pathways.51,52
A family of protein nanocompartments, encapsulin, forms ~20 nm particles in archaea 
and bacteria.53 The encapsulin proteins purified from Thermotoga maritima self-assemble 
into T = 1 60-subunit icosahedral capsids. Encapsulin capsids specifically encapsulate 
ferritin-like proteins or peroxidases, both involved in oxidative-stress response. 
Interestingly, the guest enzymes possess a unique C-terminal extension motif, which 
drives selective encapsulation by binding to a highly conserved site on the interior surface 
of encapsulin. This C-terminal sequence perhaps can act as a tag to direct the 
encapsulation of guest proteins into the interior of encapsulin capsid.53
Ferritins, a family of protein capsids abundant in all domains of life, are well known 
to play an important role in iron storage and regulation.54 Ferritins form octahedral 
capsids with 432 symmetry via self-assembly of 24 identical subunits.55 While some 
enzymes which carry out important biological functions, such as electron transfer and 
oxygen transport, require iron for their activities, excess cellular iron can cause oxidative 
damage. Ferritins act as cellular iron detoxifiers and reservoirs by catalyzing the 
mineralization of iron into hydrous ferric oxide, which is stored in their inner cavities.56,57 
The pores at the three-fold axes in the protein shell of ferritins can function as gates to 
regulate the flow of iron across the shell.58,59 The negatively charged amino acids at the 
three-fold pores create a negative electrostatic gradient that guides iron from the channel 
entrance to the active sites at the inner surface of ferritin capsids, where the Fe(II) 
becomes oxidized to Fe(III) by oxygen. The unique metal sequestration property of 
ferritins has been used to synthesize a variety of mineral cores within the protein shell.60
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1.3. Engineering Protein Capsids for Biological 
and Material Applications
1.3.1.Nanoscale Material Synthesis 
Some natural protein capsids, such as ferritins, catalyze biomineralization reactions 
and store inorganic particles in their inner cavities.54 These protein capsids provide 
several advantages for nanoparticle synthesis. For example, the confined space within the 
protein capsids can be used for generating highly monodisperse nanoparticles. Also, these 
protein capsids provide a highly charged interior surface for inducing nucleation reactions 
to trigger mineralization.59 A great deal of studies have utilized these protein capsids as 
nanosized bioreactors for the synthesis of nanoparticles within their cage-like 
structures.60,61
Engineered ferritin capsids have been used to synthesize a variety of inorganic and 
metallic nanoparticles including silver nanoparticles with a very narrow size 
distribution.62,63 The inner surface of ferritin capsids was modified with dodecapeptides, 
which have been shown to reduce silver ions to metallic silver, allowing silver ions to be 
selectively reduced within the constrained space of the ferritin capsid interior and 
generating monodisperse silver nanoparticles. Other protein capsids, such as cowpea 
chlorotic mottle virus (CCMV) capsid, have also been engineered to produce inorganic 
nanoparticles.64 Studies of ferritins reveal that the highly negatively charged interior 
surface of ferritin capsids can favor mineralization processes. Thus, the overall charge of 
the CCMV capsid interior surface was altered from positive to negative. The engineered 
CCMV capsids were demonstrated to generate iron oxide nanoparticles with 
homogeneous size distribution within the capsid.65 This strategy could potentially be
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applied to other protein capsids with different sizes to tailor-make nanoparticles with 
desired sizes.
The confined inner space of the heat shock protein (Hsp) capsid from Methanococcus 
jannaschii was used to synthesize defined polymer networks.66 Cysteines were 
engineered onto the inner surface of the Hsp capsid to provide anchor points and initiate 
the polymerization reactions. Using an azide alkyne cycloaddition reaction approach, 
branched polymers were grown selectively within the Hsp capsid. This synthetic 
approach allows the synthesis of polymer structures in a highly restricted size range. In 
addition, the encapsulated polymer provided a high-capacity reservoir of small-molecule 
binding sites for drug delivery and bio-imaging applications.
1.3.2. Drug Delivery and Bio-imaging
Protein capsids are attractive scaffolds for developing novel drug carriers and have 
demonstrated promising results.67 Their well-defined structures allow protein capsids to 
be modified by genetic or chemical methods without disrupting the overall quaternary 
structures. Further, functional molecules, such as antibodies, peptides, aptamers, 
carbohydrates, and polymers, can be conjugated onto the exterior surface of protein 
capsids to enable cell specific targeting, enhance cell uptake, or reduce immunogenicity.68
The hollow interiors of protein capsids allow capsids to encapsulate drugs or materials 
with optical or magnetic properties. In addition, the amino acids at the inner surface of 
protein capsids can be engineered to contain reactive sites, such as the reactive thiols on 
cysteines, for covalent bonding to cargo molecules. Alternatively, cargo molecules can 
also be loaded into capsids noncovalently via electrostatic interactions. By substituting
inner surface residues with positively or negatively charged residues, the loading 
efficiency of charged cargo molecules, such as DNA, RNA, or other ionic polymers, can 
be enhanced.
Numerous drug carrier systems have been generated using virus capsids as scaffolds. 
For example, the interior of bacteriophage MS2 capsid has been engineered to form 
covalent bonds with chemotherapeutic drugs, magnetic resonance imaging (MRI) 
contrast agents, positron emission tomography (PET) radioisotopes, and fluorescent 
dyes.69-71 These therapeutic molecules were attached to the MS2 capsid either by forming 
a thioether linkage with the reactive sulfhydryl group on an engineered interior cysteine 
residue or by a diazonium coupling reaction with the interior tyrosines.
CCMV capsids also have been extensively studied as potential drug carriers. A metal- 
binding peptide was fused to the N-terminus of the CCMV capsid protein that allows the 
binding of gadolinium (Gd3+), a MRI contrast agent.72 Further, in another engineered 
CCMV capsid, a clinically relevant contrast agent, gadolinium-tetraazacyclododecane 
tetraacetic acid (GdDOTA), was covalently attached to lysine residues on the inner 
surface of the CCMV capsid protein via reaction with an N-hydroxysuccinimide (NHS)
79ester.
Some virus capsids possess abilities to encapsulate negatively charged molecules, 
such as DNA, RNA, or synthetic polymers, in addition to their own genomic materials 
by forming capsid around the cargo molecules. Such abilities can be used to engineer 
drug carriers that encapsulate charged drug molecules noncovalently. For example, 
engineered hepatitis B virus capsids have been used to deliver synthetic DNA molecules 
to cell targets both in vitro and in vivo.73 In addition, hibiscus chlorotic ringspot virus
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capsid has demonstrated the ability to simultaneously encapsulate polyprotic acid- 
associated doxorubicin (an anticancer drug molecule) during capsid formation. In this 
study, folic acid was conjugated onto the drug-loaded capsids to promote selective 
cellular uptake of loaded capsids by cancer cells.74 In another study, CCMV capsid was 
used to encapsulate DNA micelles that were self-assembled from DNA oligonucleotide 
amphiphiles.75 Each DNA micelle possessed a hydrophobic core surrounded by anionic 
tails that point out from the core. The high negative charge density provided by the 
anionic tails of the DNA micelles allowed encapsulation into CCMV capsid. These DNA 
micelles can be preloaded with hydrophobic molecules that partition into the hydrophobic 
core or with hydrophilic molecules by sequence-specific hybridization to the tails of DNA 
micelles.
1.3.3.Catalysis
Protein capsids can be ideal scaffolds for developing novel bioreactors.76 Pores in the 
capsid shell usually allow small molecules (such as substrates or products) to diffuse into 
and out of the capsid interior but keep big molecules (such as enzymes) inside the capsids. 
Indeed, bacterial microcompartments represent a successful example of natural 
bioreactors. Inspired by bacterial microcompartments, artificial nanobioreactors have 
been constructed using engineered protein capsids and have shown promising results as 
novel catalysts.77-79 Further, the monodisperse inner space and the well-defined structure 
make protein capsids attractive as model systems for studying enzymatic reactions in a 
confined space.
The CCMV capsid has been engineered as a viral nanoreactor by encapsulating
horseradish peroxidase (HRP).80 The assembly states of CCMV capsid can be 
dynamically switched between dimers and capsids at different pH values. For instance, 
CCMV protein forms a 180-subunit icosahedral capsid at pH 5 and the capsid dissociates 
into 90 dimers at pH values above 7.81,82 Thus, HRP encapsulation can be achieved by 
mixing the disassembled CCMV proteins with HRP at pH 7 then subsequently bringing 
the pH down to 5 where the CCMV protein subunits assemble around the HRP molecules. 
Since there is no intrinsic affinity between HRP and the CCMV capsid, the encapsulation 
of HRP during CCMV capsid assembly depends on random diffusion, which results in a 
low yield of encapsulated enzymes. Consequently, those capsids that did take up HRP 
could be safely assumed to possess only one copy of the enzyme, which enabled single­
molecule measurements of HRP kinetics. The observed activity revealed that the capsid 
shell is not only permeable to both substrates and products but can also regulate their 
diffusion across the capsid shell in response to pH-dependent changes in the size of the
O Apores.80
In a follow-up study, a noncovalent anchoring approach was used to improve the 
control of guest encapsulation.83 This strategy involved modification of both the CCMV 
capsid proteins and the guest enzymes with a positively charged peptide tag and a 
negatively charged peptide tag, respectively. Charge complementarity triggers the 
formation of a coiled-coil between the two peptide tags, driving encapsulation of the guest 
protein by the CCMV capsid. This strategy allows precise control over the number of 
encapsulated enzymes in each CCMV capsid.77 The enzyme lipase B was encapsulated 
in this manner and was found to convert substrate to product more efficiently than free 
lipase B in bulk solution. However, increasing the number of enzyme molecules in the
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capsid did not increase the overall reaction rate at a constant concentration of total 
enzyme.
In another example, cargo enzymes were packaged into bacteriophage QP particle via 
RNA-directed encapsulation in vivo19 In brief, a bifunctional RNA aptamer was 
engineered containing two binding domains, one to bind to the tagged cargo enzyme and 
one to bind to the capsid interior. Coproduction of capsid protein, guest enzyme, and 
RNA-aptamer led to the formation of capsids loaded with guest enzymes in vivo. The 
encapsulated enzymes were still catalytically active. Further, the protein capsid showed 
the ability to stabilize and protect the encapsulated enzymes against heat denaturation, 
protease degradation, and hydrophobic adsorption.
Bacteriophage P22 capsid was also used to generate a nanoreactor.78 The P22 capsid 
is formed by self-assembling 420 copies of P22 capsid protein around a structural 
template formed by 100-330 copies of P22 scaffold protein, resulting in a T = 7 
icosahedral capsid. By fusing the guest molecules with the scaffold proteins, guest can be 
encapsulated into P22 capsid during capsid assembly.84 In this study, a truncated 
bacteriophage P22 scaffolding protein sequence was fused to the C-terminal end of the 
target enzyme, alcohol dehydrogenase D (AdhD). The P22 scaffolding protein-AdhD 
fusion protein promotes the specific encapsulation of cargo enzyme into the P22 capsid 
interior with a high loading yield during P22 capsid formation in vivo. Further, incubation 
of the P22 capsid at different temperatures can trigger the P22 capsid to transform into 
different capsid structures, including an expanded capsid structure and a “wiffleball” 
structure. Enzyme activity studies of the enzyme-loaded P22 capsids reveal that the 
overall activity of the encapsulated enzyme can be altered by transforming P22 capsid
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into different morphological states, which change the internal volume and the porosity of 
the capsid.78
1.4. Switches for Capsid Assembly
1.4.1.Natural Capsid Assembly Switches 
Protein capsids have been used to encapsulate different types of cargo molecules for 
many applications, as described above. For small cargoes, capsid loading can be carried 
out with intact capsids, but this strategy only works for cargoes that can fit through the 
capsid pores. However, the self-assembly/disassembly of some virus capsids can be 
controlled by changing solution conditions, allowing simultaneous cargo loading and 
capsid formation in vitro. Because such in vitro encapsulation approaches are usually 
performed in simpler and more controlled conditions, they could generate more 
homogeneous encapsulation products than in vivo encapsulation approaches. Further, in 
vitro cargo loading via controllable capsid assembly could expand the range of potential 
cargo molecules, increasing the versatility of capsids for bionanotechnological 
applications.
The pH-dependent assembly of CCMV capsid, which has been discussed above, 
provides a well-known example of natural capsid assembly switches. The assembly states 
of CCMV capsid can be freely exchanged between dimers and 180-subunit icosahedral 
capsids by changing the buffer pH.81 In another example, hepatitis B virus capsid also 
exhibits an assembly switch, which can be induced to assemble by increasing the ionic 
strength. Wild-type hepatitis B virus capsid consists of 240 identical protein subunits, and 
these subunits are arranged into a T = 4 icosahedral capsid. A truncated hepatitis B virus
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capsid protein forms dimers after purification from E. coli cells. These dimers reassemble 
into wild-type-like capsids in response to high ionic strength. Interestingly, mild 
denaturing conditions (1.75 to 3.25 M of urea) can be used to trigger the dissociation of 
hepatitis B virus capsids without unfolding the dimeric building blocks.85,86
Capsid assembly can also be induced upon metal ion binding. Studies on icosahedral 
murine polyomavirus (MPV) capsid demonstrated that MPV capsid self-assembly from 
pentameric building blocks can be triggered in vitro by adding Ca2+ ions.87 Further, 
lowering the pH or increasing the ionic strength can also induce the self-assembly of 
MPV capsids. Although a detailed understanding of these natural capsid assembly 
switches is lacking, protein-protein interactions at the interfaces of building blocks should 
be crucial in determining the assembly states of protein capsids. Thus, knowledge of 
protein-protein interactions could help further our understanding of virus capsid assembly 
and aid in the development of artificial capsid assembly switches.
1.4.2. Engineering Capsids for Controlled Assembly
The use of natural capsid assembly switches can be a very attractive strategy for cargo 
loading. However, not all protein capsids possess this feature. Further, the solution 
conditions that trigger natural assembly switches may sometimes be incompatible with 
the desired application. Such limitations could be overcome by using rationally designed 
artificial capsid assembly switches as alternatives. Previously reported attempts to design 
artificial capsid assembly switches exploit various triggers, including metal ion-induced 
capsid assembly, pH-dependent capsid assembly, or temperature-dependent capsid 
assembly.88-91
1.4.2.1. Metal-induced Capsid Assembly
Some protein oligomerizations can be controlled upon binding of small molecules or 
metal ions across the protein-protein interfaces. Such strategies could be useful for 
designing a potential switch to regulate assembly of a protein capsid. Ferritin capsid, 
which is lacking a natural capsid assembly switch, was used as a model system for 
engineering artificial capsid assembly switches.88 Metal-induced ferritin capsid formation 
was achieved by engineering two metal coordination sites, which consisted of two pairs 
of histidine residues for each binding site, at the two-fold axes of the ferritin capsid. Each 
binding site is capable of forming a planar coordination with one copper ion. The 
monomeric building blocks used for studying the metal-induced capsid formation also 
included three additional mutations of the interfacial residues in order to disrupt native 
hydrogen-bonding interactions, which stabilize the wild-type ferritin capsid formation. 
The resulting ferritin variant, called MIC1, was purified from inclusion bodies as 
monomers in the presence of EDTA. Upon removal of EDTA and addition of copper ions, 
MIC1 was converted into a 24-subunit capsid. However, the metal-induced MIC1 capsid 
did not disassemble upon removing the metal ions with EDTA.
In another example, CCMV capsid was also engineered to allow metal-induced capsid 
assembly.91 As described previously, CCMV capsid proteins can be reversibly assembled 
and disassembled by changing buffer pH. The usefulness of this switch is limited by the 
fact that the capsid disassembles into protein dimers at physiological pH. Therefore, an 
assembly switch that can stabilize the CCMV capsid at high pH could be valuable. In the 
metal-induced CCMV capsid assembly study, the N-termini of the CCMV subunits, 
which are located at the six-fold and five-fold axes of the capsid, were fused to
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hexahistidine sequences, which provided a metal coordination motif. Polyhistidine 
sequences form strong multivalent interactions with metal ions; therefore, this 
modification is commonly used for protein purification by affinity chromatography. The 
N-terminal hexahistidine modified CCMV proteins, named His-CPs, formed capsid-like 
assemblies at pH 7.5 when nickel ions were added to the buffer. The nickel induced 
CCMV assemblies can be disassembled by adding EDTA to remove the nickel ions.
1.4.2.2. pH-dependent Capsid Assembly
Some protein capsids, such as CCMV capsid, have an intrinsic ability to switch their 
assembly states in response to changing the environmental pH. Inspired by this type of 
naturally occurring switch, the protein interfaces of the E2 subunit in pyruvate 
dehydrogenase capsid were modified to enable pH-responsive disassembly.90 The 
pyruvate dehydrogenase capsid is formed by 60 E2 subunits, which self-assemble into a 
dodecahedral capsid with 532 symmetry. A cluster of six histidine residues was found at 
the three-fold axis of wild-type E2 capsid. Since the imidazole group of histidine typically 
has a pKa value of ~6-7, histidine is mainly neutral at physiological pH but can be 
protonated and carry positive charge when the pH is lowered below 6.5.92,93 Therefore, 
the histidine residues at the three-fold axis of the E2 capsid can be used to introduce 
charge-charge repulsion at low pH condition. The wild-type E2 forms stable capsids at 
both pH 7.4 and pH 5.0. However, after deleting the first 44 amino acids from the N- 
terminus, the truncated E2 protein (AN-E2) assembled into capsids upon production in 




1.4.2.3. Temperature-dependent Capsid Assembly
CCMV capsid has also been engineered for temperature-dependent assembly by 
attaching temperature-responsive elastin-like polypeptides (ELPs) to the capsid protein.91 
ELPs contain a repeating Val-Gly-Xaa-Gly sequence, in which the Xaa can be any natural 
amino acid except proline. ELPs have shown reversible switching from an extended 
water-soluble state to a hydrophobic state in response to the temperature.94,95 The 
transition temperature of ELPs can be varied by multiple factors such as the residue at the 
Xaa position, the number of repeats, and the protein and salt concentrations. In the 
temperature-dependent CCMV capsid assembly study, an ELP sequence was fused to the 
N-terminus of the CCMV capsid protein. The resulting protein, ELP-CP, was able to form 
a wild-type-like T = 3 capsid at pH 5.0, but gave only a small yield of capsids in pH 7.5 
buffer containing 1.3 M NaCl at 20 °C. However, upon incubation at 35 °C for 15 min, 
most of the ELP-CP proteins assembled into T = 1 capsids.
1.5. Lumazine Synthase 
Lumazine synthase can be an interesting model system for studying protein capsid 
self-assembly because both capsid-forming and noncapsid forming lumazine synthase 
homologs have been observed. Lumazine synthase is found in bacteria, archaea, fungi, 
and plants, and catalyzes the formation of 6,7-dimethyl-8-ribityllumazine, the immediate 
precursor of riboflavin, from 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione and 
3,4-dihydroxy-2-butanone 4-phosphate.96 Riboflavin synthase catalyzes the addition of 
two 6,7-dimethyl-8-ribityllumazine molecules to form riboflavin and 5-amino-6- 
ribitylamino-2,4(1H,3H)-pyrimidinedione (Figure 1.4). A noteworthy feature of this two-
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Figure 1.4. The reactions catalyzed by Bacillus subtilis lumazine synthase/riboflavin 
synthase complex.
step process is the cycling of material between the two enzyme active sites.
Lumazine synthase possesses various quaternary structures among different 
organisms, although the tertiary fold is highly conserved. In some fungi and bacteria, such 
as Saccharomyces cerevisiae, Magnaporthe grisea, Candida albicans, 
Schizosaccharomyces pombe, and Mycrobacterium tuberculosis, lumazine synthase 
forms a pentameric arrangement of five identical monomers (Figure 1.5A).97-101 
Lumazine synthase from Brucella abortus assembles as a D5-symmetric dimer of 
pentamers (Figure 1.5B).102 Interestingly, lumazine synthases from some other bacteria 
and plants, such as Bacillus subtilis, Escherichia coli, Aquifex aeolicus, Salmonella 
typhimurium, and Spinacia oleracea, form 60-subunit capsids (Figure 1.5C).99,103-106 
Typically, lumazine synthase capsids consist of 12 pentameric building blocks, arranged 
into T = 1 dodecahedra with outer diameters of about 160 A. However, multiple assembly 
states of B. subtilis lumazine synthase (BsLS) capsid have been observed in different 
buffer systems, at different pH values, and with different ligands. Besides T = 1 capsids, 
expanded T = 3 capsids, with a diameter around 29 nm, and even T = 4 capsids of BsLS 
have been observed by using transmission electron microscopy (TEM).107
BsLS forms a multi-enzyme nanoreactor by encapsulating a riboflavin synthase trimer 
in the inner space to enhance catalytic efficiency via substrate channeling.43,46 An 
approximately 16 A pore (Ca to Ca) located at the five-fold symmetry axis of the lumazine 
synthase pentamer has been proposed as the route by which substrates and products 
diffuse across the capsid shell and access the active sites at the subunit interfaces within 
the pentamers.99 However, structural analysis indicates that this pore is too narrow to 
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Figure 1.5. Structural comparison of lumazine synthase family members. (A) Surface 
representation of S. pombe lumazine synthase pentamer (PDB ID:1KYV) viewed along 
the five-fold symmetry axis. (B) Surface representation of B. abortus lumazine synthase 
dimer-of-pentamers (PDB ID: 1XN1). One pentamer was colored orange and the other 
was colored grey. (C) left: surface representation of B. subtilis lumazine synthase capsid 
(PDB ID: 1RVV) viewed down the five-fold symmetry axis. One of the 12 pentameic 
building blocks was colored as cyan, the others were colored grey. Right: cross-section 
of the B. subtilis lumazine synthase capsid, showing the inner and outer diameters
lumazine synthase (AaLS) variant, which contains a four amino acid insertion, 
homologous to a sequence found in pentameric lumazine synthase, forms an expanded 
T = 3 capsid.107 This altered assembly demonstrates the plasticity of protein-protein 
interfaces in the capsid. Cryo-electron microscopy studies suggest that this expanded 
capsid can be a consequence of self-assembling expanded pentameric building blocks 
with widened pores in the centers of the pentamers.108 This expanded pentameric structure 
provides a possible model for an alternative conformation of the lumazine synthase 
pentamer. Based on this observation, a model of capsid breathing during the catalytic 
cycle of lumazine synthase was proposed.108 This model proposed that the expanded 
T = 3 capsid is formed by expanded pentamers with unoccupied substrate binding sites. 
The expanded pentamers in the T = 3 capsid contain widened pores that allow transport 
of substrates across the capsid wall to the active sites. Upon binding of substrates, the 
pentamers change to a closed state and form a T = 1 capsid. After the catalytic reaction is 
done, the products are released from the active site and the pentamers revert back to the 
expanded state with widened pores, which allows the products to diffuse out of the capsid 
interior.
Lumazine synthase capsids have been engineered as molecular containers for a variety 
of molecules.109,110 For example, a BsLS based bionanoreactor has been utilized to 
synthesize iron oxide nanoparticles.110 One homolog of BsLS, AaLS, is a particularly 
promising scaffold for engineering novel molecular containers.
The AaLS capsid possesses many desirable features for protein engineering. One 
important property of AaLS is its extremely high thermostability, with a melting 
temperature of 119.9 °C, which likely stems from the fact that this protein is derived from
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a hyperthermophilic bacterium.103 Further, the AaLS capsid can be produced 
recombinantly in E. coli with high yields. An additional advantage for protein redesign is 
the availability of a high-resolution crystal structure. Indeed, AaLS has been engineered 
as a molecular container for both protein and RNA guests, based on charge 
complementarity.111-114
To encapsulate proteins, four residues per monomer (R83, T86, T120, and Q123), 
located at the inner surface of the AaLS capsid, were simultaneously mutated to 
glutamates to generate a variant named AaLS-neg.111 Surprisingly, AaLS-neg forms a 
180-subunit T = 3 capsid that has 720 additional negative charges relative to wild-type 
AaLS. Charge complementarity between AaLS-neg and a cationic R 10 tag fused to the 
green fluorescent protein (GFP) provided affinity between the capsid and this model guest 
protein. Coproduction in E. coli resulted in the encapsulation of three to four GFP-R10 
molecules per AaLS-neg capsid.
The loading capacity of R 10-tagged guest proteins in the AaLS-neg capsid was further 
optimized by a directed evolution approach. In this experiment, the R 10-tag was fused to 
the C-terminus of the cytotoxic HIV protease. Coproduction of the tagged protease and 
AaLS-neg conferred a growth advantage on the cells relative to a control coproducing the 
tagged protease and wild-type AaLS. Presumably, confinement in AaLS-neg capsids 
prevents HIV protease from destroying cellular proteins, which enabled the selection of 
capsid variants that more efficiently encapsulate this toxic enzyme. After four rounds of 
selection, an AaLS variant, AaLS-13, was identified that showed an almost 10-fold higher 
encapsulation efficiency than the parent AaLS-neg.112 The increased encapsulation 
efficiency likely stems from a further increase in the number of negatively charged
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residues on the inner capsid surface.
AaLS-13 has also shown the ability to encapsulate supercharged GFP(+36), a variant 
of GFP in which 29 surface-exposed residues were mutated to positively charged amino 
acids, in vitro. By optimizing the concentrations of capsid and guests, up to 100 GFP(+36) 
molecules can be loaded per capsid. When produced in E. coli cells without a cationic 
guest, AaLS-13 purifies as a mixture of pentamers, higher order oligomers, and fully 
assembled capsids. Interestingly, the encapsulation of GFP(+36) in vitro works equally 
well with either intact AaLS-13 capsids or lower-order assemblies. The former result 
suggests that the assembly state of empty AaLS-13 capsids may be dynamic. The latter 
result suggests that cationic guests can act as templates for AaLS-13 capsid assembly.
In contrast to AaLS-neg and AaLS-13, another AaLS variant, AaLS-pos, was 
engineered with a positively charged inner surface. In this case, charge complementary 
was used to encapsulate cellular RNAs.113 AaLS-pos contains four amino acid 
substitutions per monomer (T86R, D90N, T120R, and E122R) yielding a net interior 
charge of up to +240, providing a much more highly cationic environment compared to 
wild-type capsid, which is expected to possess a net interior charge of -60. After 
production in and purification from E. coli cells, AaLS-pos forms 60-subunit T = 1 
capsids containing cellular RNA molecules ranged in size approximately from 50 to 400 
bases in length. AaLS-pos represents a promising starting point for the development of 
novel nucleic acid encapsulation systems which could be used as delivery vehicles for 
therapeutic molecules, such as siRNAs.
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1.6. Aims of This Thesis 
The work presented in this thesis seeks a more detailed understanding of the 
interactions involved in the self-assembly of AaLS capsids in order to extend its 
functional capabilities. The results should contribute to the long term goals of this project, 
namely the design of novel AaLS encapsulation systems useful for developing drug 
delivery systems and enzymatic nanoreactors.
Here, the AaLS capsid is viewed as a dodecamer of pentamers, in which the 
interactions across the pentamer-pentamer interfaces are essential for capsid formation 
but not the stability of individual pentamers. Chapter 2 describes a detailed analysis of 
important interaction sites at the AaLS pentamer interfaces. Consequently, AaLS 
assembly can be halted at the pentamer stage by making a small number of well-chosen 
pinpoint mutations that alter interactions that stabilize the interfaces between pentamers.
Using knowledge of important interactions at the pentamer interfaces in the AaLS 
capsid, a redox-based assembly switch was designed, constructed, and characterized, as 
outlined in Chapter 3. An engineered pentameric AaLS variant, AaLS-switch-red, in 
which a unique cysteine was introduced at a position corresponding to the three-fold 
symmetry axis of the capsid, was used as a starting point for capsid assembly in vitro. 
Upon modification with thiophenol, the resulting adduct, AaLS-switch-ox, was found to 
self-assemble into 60-subunit capsids, presumably by mimicking a hydrophobic 
interaction present in wild-type capsids.
To better control AaLS capsid self-assembly in vitro, a pH-dependent capsid assembly 
switch that can reversibly interconvert between assembly states was designed, 
constructed, and characterized, as described in Chapter 4. Three histidine mutations per
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polypeptide were introduced near the three-fold symmetric pentamer interface. The 
titratable histidine side chains were used to generate positive charge at low pH, driving 
capsid disassembly by causing charge repulsions that destabilize the pentamer interface. 
The capsids could be reassembled by increasing the pH back to its original value since 
these histidines minimally affect capsid assembly when neutral.
The results in this thesis demonstrate the ability to control AaLS capsid assembly in 
vitro, which could expand the range of potential cargo molecules for this scaffold. These 
controllable assembly switches enhance the versatility of the AaLS capsid and pave the 
way for its use in many applications, including the development of bio-imaging agents, 
nanocontainers, or drug delivery systems.
CHAPTER 2
CONVERSION OF A DODECAHEDRAL PROTEIN CAPSID 
INTO PENTAMERS VIA MINIMAL POINT MUTATIONS
Reprinted with permission from Chen, H.-N. and Woycechowsky, K.J. Conversion of a 
dodecahedral protein capsid into pentamers via minimal point mutations. Biochemistry 
2012, 51: 4704-4712. Copyright 2012 American Chemical Society.
2.1. Introduction
Many proteins form symmetrical, nanoscale architectures from multiple copies of 
identical polypeptide subunits.1 These assemblies are held together by noncovalent 
interactions at the protein-protein interfaces.13 However, the energetic contributions of 
individual residues to the stability of protein-protein interfaces are often unevenly 
distributed.25,27 Subtle changes can sometimes convert one quaternary structure into 
another. General rules for predicting quaternary assembly have been slow to emerge.115-
117
The engineering of nanostructures demands a thorough understanding of the basis 
for protein self-assembly.29 In particular, self-assembled protein capsids represent a class 
of nanoscale scaffold that holds much promise for various applications, including drug 
delivery, catalysis, and materials synthesis.67,76,118,119 Indeed, much effort has gone into 
repurposing capsids to act as containers for a wide variety of nonphysiological cargo 
molecules, such as proteins, nucleic acids, small molecules, and inorganic 
nanoparticles.75,79,83,84,120-125 The controlled and efficient loading of these containers can 
be facilitated by the ability to interconvert the capsid with lower order quaternary 
states.83,126 Viral capsids possess inherent switches that allow the efficient disassembly 
and reassembly in response to solution conditions.127,128 In principle, it should also be 
possible to engineer the interconversion of quaternary structures between capsids and 
lower order assemblies.
The capsid formed by lumazine synthase from Aquifex aeolicus (AaLS) is a 
promising scaffold for engineering novel molecular encapsulation systems.111,112,114 
AaLS self-assembles into a 60-subunit dodecahedral capsid (Figure 2.1A) with a diameter
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Figure 2.1. Structure and protein-protein interactions of the AaLS capsid. (A) Surface 
representation of the AaLS capsid. All of the pentamers are colored differently. In the 
pentamer at the front of the capsid only, each subunit is colored individually. The rest of 
the pentamers are colored uniformly. (B) Side-view of two adjacent pentamers extracted 
from the crystal structure of the AaLS capsid. The backbones of the pentamers are shown 
in brown and blue. Residues comprising the ionic, hydrogen bonding, and hydrophobic 
interaction sites are shown in space-filling representation. (C) Ribbon diagram of a 
pentamer extracted from the crystal structure of AaLS capsid. The view on the left is from 
the outside of the capsid, and the view on the right is from the inside of the capsid. Amino 
acids that contribute to the ionic, hydrogen bonding, and hydrophobic interaction sites 
are colored cyan and indicated by arrows. (D) The ionic interaction site. (E) The hydrogen 
bonding site. (F) The hydrophobic interaction site.
of 16 nm, enclosing an empty chamber approximately 9 nm across.103 This capsid is 
extremely stable, with a reported melting temperature of 120 °C. While the AaLS capsid 
presumably assembles from 12 pentamers, lone pentamers of AaLS have never been 
isolated.
Despite an inability to reversibly disassemble AaLS in vitro, this capsid has been 
engineered to encapsulate guest proteins in vivo using a charge complementarity 
strategy.111,112 In this system, AaLS variants with extra negative charges at the inner 
surface of the capsid act as hosts for guest proteins bearing a positively charged 
decaarginine (R 10) tag. Encapsulation complexes are formed by coproduction of the AaLS 
variant and guest protein in Escherichia coli cells. Loaded capsids can be purified from 
these cells, but are essentially dead-end complexes. For example, a rationally designed 
AaLS variant (AaLS-neg) in which four residues at the inner capsid surface have been 
changed to glutamates can encapsulate R 10-tagged green fluorescent protein or HIV 
protease .112 Interestingly, the addition of negatively charged residues at the inner surface 
of the capsid causes a dramatic expansion of the capsid structure, as AaLS-neg forms 
180-subunit capsids with a diameter of 28 nm. Directed evolution of AaLS-neg to 
optimize the encapsulation of R 10-tagged HIV protease gave a variant (AaLS-13) with 
increased negative charge density at the inner surface that formed capsids 34 nm in 
diameter, over twice the size of wild-type AaLS.112 When produced in the absence of the 
HIV protease guest, AaLS-13 is isolated a mixture of intact capsids and capsid fragments. 
These fragments can assemble into capsids in the presence of positively charged guest 
protein.114 These observations suggest that it should be feasible to tip the balance between 
different assembly states of AaLS in a controlled fashion.
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In Nature, the lumazine synthase (LS) family of proteins is rich in quaternary 
structural diversity. In addition to 60-subunit capsids, many homologs form 
pentamers.97,99 Decamers have also been observed that assemble via the dimerization of 
pentamers.129 Various explanations for what determines the extent of assembly, in 
particular capsid versus pentamer, have been put forward based on homology. For 
example, phylogenetic and structural analysis led to the identification of eight sequence 
positions that have different patterns of conservation between capsid-forming and 
pentameric LSs.130 Structural comparisons have also highlighted potential suspects 
responsible for determining the extent of assembly. Persson et al."  purported that a 
proline residue near the N-terminus of pentameric LSs could prevent capsid formation by 
breaking a P-strand that aligns with a P-sheet of an adjacent subunit in capsid-forming 
LSs. Alternatively, Braden et al.131 suggested that the presence of a five-residue kink in 
the C-terminal helix is important for capsid formation. In addition, it was also proposed 
that a four-residue insertion in the loop connecting the fourth and fifth a-helices of a 
pentameric LS could be responsible for preventing further assembly.97 This latter 
hypothesis was tested experimentally by making the insertion in AaLS.107 The resulting 
variant still formed capsids, albeit with an expanded structure.
Here, we aimed to identify structural determinants of capsid formation in AaLS by 
targeted mutation of residues that define the pentamer-pentamer interfaces of the capsid. 
Using visual inspection of the available high-resolution crystal structure, we identified 
specific noncovalent interactions between side chains on adjacent pentamers in the AaLS 
capsid. These interactions were disrupted by strategic amino acid substitutions, 
effectively preventing capsid formation by halting assembly at the pentamer stage.
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2.2.Results
2.2.1. Design of AaLS Variants 
The AaLS capsid can be viewed as a dodecamer-of-pentamers (Figure 2.1A). The 
hierarchical assembly of the capsid from pentameric building blocks is further supported 
by the observation that the assembly of some homologs halts at the pentamer stage.97,99 
To understand the determinants of capsid formation in AaLS, we examined the interface 
between pentamers in the available crystal structure (PDB ID: 1hqk).103 Three distinct 
types of interaction sites (hydrogen bonding, ionic network, and hydrophobic cluster) are 
found that presumably hold the pentamers together in the capsid (Figures 2.1B-F).
The hydrogen bonding interaction found at the two-fold symmetry axis of the capsid 
is formed by two histidine residues, H41 and H41', from two adjacent pentamers (Figure 
2.1E). The length of this hydrogen bond is 2.7 A, which marks the point of closest 
approach between two pentamers. The ionic network, located next to the two-fold 
symmetry axis, is highly conserved in dodecahedral lumazine synthases and has been 
previously reported to play an important role in AaLS capsid stability.107 Two arginine 
residues, R21 and R40', from two different pentamers lie at the center of this network 
(Figure 2.1D). Their guanidino side chains are stacked on top of each other at a distance 
of 3.3 A and are surrounded by the acidic residues E5, E145, and D36'. The third pentamer 
interaction site involves residues L121 and I125, which form a hydrophobic cluster at the 
three-fold symmetry axis interface near the inner surface of the capsids (Figure 2.1F).
We hypothesized that we could change the AaLS assembly state from a 60-subunit 
capsid to a pentamer by mutating a subset of the residues listed above. To test this 
hypothesis, a series of AaLS variants were designed to achieve the targeted disruption of
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the noncovalent interactions at the interface between pentamers in the wild type AaLS 
capsid. Among the amino acids listed above, we focused on five amino acids (R21, R40, 
H41, L121, and I125) in particular. Substituting negatively charged glutamates in place 
of these amino acids should both abolish stabilizing interactions and introduce charge- 
charge repulsion at the native pentamer-pentamer interface. Alternatively, introducing 
arginine residues at some of these positions could achieve the same effect while also 
potentially generating steric clashes.
2.2.2. Screening Assembly State by SEC 
A series of AaLS variants containing point mutations designed to prevent the 
formation of stabilizing noncovalent interactions between pentamers were produced in 
BL21 DE3 E. coli cells and purified by ammonium sulfate precipitation followed by 
anion-exchange chromatography. The assembly states of these AaLS variants were 
estimated by SEC with a sephacryl S-400HR column (Tables 2.1 and 2.2). As suggested 
by our AaLS capsid structure analysis, R40, H41, L121, and I125 all contribute to capsid 
assembly. Indeed, simultaneous mutation of the ionic, hydrogen bonding, and 
hydrophobic interaction sites (R40E/H41E/L121E and R40E/H41E/I125E) appeared to 
give stable pentamers (Figure 2.2).
Mutating just the ionic and hydrogen bonding sites (R40E/H41E and 
R21E/R40E/H41E) has no effect on the capsid assembly. Interestingly, changing both 
residues at the hydrophobic site (L121E/I125E) causes the capsid to expand, which may 
reflect partial destabilization. This expanded capsid species could contain 180-subunits, 
as has been seen in other variants of AaLS.107,111 On the other hand, simultaneous
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Table 2.1. Assembly states of AaLS variants.
Protein # of pentamersa
wild type AaLS 12





R40E/L121E/1125E- .  oc2 or 3c
AaLS











a Determined by SEC using a sephacryl S-400HR column. The number of pentamers is 
defined as the total number of protein subunits divided by five.
b This protein eluted similarly to AaLS-neg, which forms a 180-subunit capsid. Thus, this 
variant probably assembles from 12 pentamers and 20 hexamers, rather than from 36 
pentamers.
c These proteins eluted at volumes between those expected for a dimer-of-pentamers and 
a trimer-of-pentamers.
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Table 2.2. SEC peak elution volumes for the AaLS variants.
Protein S-400 elution volume (mL) S-300 elution volume (mL)
Wild type AaLS 69.4 38.9“
Wild type ScLS 88.0 71.0
R40E/H41E-AaLS 69.6 n.d. *
R21E/R40E/H41E-AaLS 69.7 n.d. *
L121E/I125E-AaLS 57.1 n.d. *
R40E/L121E/I125E-AaLS 79.8 n.d. *















-R40S/H41 S/1125S TV -
R40E/H41E/I125E
R40E/H41E/L121E
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Figure 2.2. SEC elution profiles of the AaLS variants. Proteins were injected onto a 
sephacryl S-400HR column. AaLS (bottom trace) and ScLS (top trace) are standards 
representing 60-subunit capsid and pentamer, respectively.
disruption of either the ionic and hydrophobic interactions (R40E/L121E/I125E) or the 
hydrogen bonding and hydrophobic sites (H41E/L121E/I125E) is sufficient to hinder 
capsid formation, but these variants still assemble beyond the pentamer stage, perhaps 
forming dimers-of-pentamers or trimers-of-pentamers. Introducing arginines instead of 
glutamates at the hydrogen bonding and hydrophobic sites seems to fully prevent any 
higher order assembly of the pentamers (Figure 2.2). Indeed the H41R/L121R variant 
might possess the minimal set of mutations sufficient to convert the AaLS capsid to 
pentamers.
To check for the role of charge repulsion in preventing capsid assembly, we made the 
R40S/H41S/I125S variant. SEC analysis showed a similar elution profile to the analogous 
R40E/H41E/I125E variant (Figure 2.2), indicating that the introduction of extra 
Coulombic repulsion at these positions is not necessary to keep the pentamers from 
coming together.
The AaLS variants described above were designed without consideration of sequence 
homology. Nontheless, an amino acid sequence alignment of AaLS with its pentameric 
homolog from S. cerevisiae (ScLS) reveals differences at positions 40, 41, and 121 
(Figure 2.3). Therefore, we made the R40S/H41L/L121E variant of AaLS in which the 
amino acids at these positions correspond to those found in ScLS. This variant and ScLS 
show similar elution profiles by SEC (Figure 2.2), suggesting that these positions may 
have been important in the evolution of LS quaternary structure.
The pentameric variants identified above by SEC with the S-400HR column were also 
injected onto an S-300HR column, which has an optimal size separation range for smaller 
proteins than the S-400HR column. The elution profiles from the S-300HR column
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AaLS -----------mqiy GKLTAEGLRF GIVAS FNHA LVDRLVEGAI 35
ScLS MAVKGLGKPD QVYDGSKIRV GIIHA WNRV IIDALVKGAI 40
AaLS DCIVR GGRE EDITLVRVPG SWEIPVAAGE LARKED---- 71
ScLS ERMV GVEE KNIIIETVPG SYELPWGTKR FVDRQAKLGK 80
AaLS -IDAVIAIGV LIRGATPHFD YIASEVSKGL ANLSLELRKP 110
ScLS PLDVVIPIGV LIKGSTMHFE YISDSTTHAL MNLQEKVDMP 120
AaLS ITFGVITADT LEQAIERAG- ---TKHGNKG WEAALSAIEM 146
ScLS VIFGLLTCMT EEQA ARAGI DEAHSMHNHG EDWGAAAV M 160
AaLS ANLFKSLR- !154
ScLS AVKFGKNAF 169
Figure 2.3. Comparison of capsid-forming AaLS and pentameric ScLS. (A) Amino acid 
sequence alignment of AaLS and ScLS. Positions involved in the ionic, hydrogen 
bonding, and hydrophobic interaction sites between pentamers in the AaLS capsid are 
colored blue, green, and red, respectively. Positions 40, 41, and 121 (AaLS numbering) 
are highlighted in yellow. (B) Superimposition of single subunits of AaLS (gray) and 
ScLS (cyan). (C) Close-up view of AaLS R40/H41 (ScLS S45/L46) region. (D) Close- 
up view of AaLS L121/I125 (ScLS E131/L135) region.
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exhibited similar trends as the S-400HR column (Table 2.2).
2.2.3. Sedimentation Equilibrium Studies 
SEC is a low resolution method for determining quaternary structure. While the results 
described above unambiguously show a shift to a much lower assembly state for some of 
the AaLS variants, our designation of the slowest eluting variants as pentamers was 
somewhat tentative. Therefore, we turned to sedimentation equilibrium experiments in 
order to confirm the subunit stoichiometries. For all variants, the sedimentation 
equilibrium data fit well to a single ideal species model and gave predicted masses close 
to that calculated for the pentamer (Table 2.3, Figures 2.4 and 2.5).
2.2.4. Assessing Folding and Stability of AaLS Variants 
To determine whether the dramatic changes in quaternary structure were accompanied 
by large changes in folding and stability, we utilized CD spectroscopy. LS is a member 
of the a  and P (a/p) class of protein structure. Far-UV CD spectra were obtained to 
compare the secondary structure content of the AaLS variants. All of the spectra displayed 
broad minimum between 222 nm and 208 nm, typical of an a/p protein (Figure 2.6A). 
The similar shapes of the spectra for wild-type AaLS and all of the variants indicates that 
none of the mutations induced major changes in overall secondary structure. The 
H41R/L121R-AaLS and R40E/H41E/I125E-AaLS variants had the lowest signal 
intensities (~12% to 16% less negative 9 values than wild-type AaLS between 220 nm 
and 208 nm), but these differences are likely within the scatter of the experiment (Figure 
2.7). Thus, the secondary structure contents of the variants are all similar to wild-type
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"Pentameric molecular weights were obtained by calculating the monomeric molecular 
weight from the amino acid sequence and multiplying by five.
bObserved molecular weights were determined by fitting the data from sedimentation 
equilibrium experiments to a single ideal species model.




Figure 2.4. Plots of sedimentation equilibrium data. All samples were spun at two 
different concentrations (0.50 mg/mL and 0.25 mg/mL). (A) Wild type AaLS was spun 
at 4000 rpm (brown and light blue for 0.50 mg/mL and 0.25 mg/mL samples, 
respectively) and 5000 rpm (purple and light green for 0.50 mg/mL and 0.25 mg/mL 
samples, respectively). (B)-(F) Samples were spun at 12500 rpm (red and blue for 0.50 
mg/mL and 0.25 mg/mL samples, respectively) and 15000 rpm (green and orange for 
0.50 mg/mL and 0.25 mg/mL samples, respectively). (B) Wild-type ScLS. (C) 
R40E/H41E/L 121E-AaLS. (D) R40E/H41E/I125E-AaLS. (E) R40S/H41S/I125S-AaLS. 
(F) H41R/L121R-AaLS. Black curves represent ideal curves derived from fitting the data 
to a single ideal species model in all cases. Residuals for each data set are shown above 
the absorbance plots.
50
Figure 2.5. Additional sedimentation equilibrium data used in the analysis of some 
variants. (A) Wild-type AaLS was spun at a concentration of 0.13 mg/mL and rotor 
speeds of 4000 rpm (pink) and 5000 rpm (brown). (B) ScLS-wt was spun at a 
concentration of 0.13 mg/mL and rotor speeds of 12500 rpm (red) and 15000 rpm (green). 
(C) R40E/H41E/L121E-AaLS was spun at a concentration of 0.13 mg/mL and rotor 
speeds of 12500 rpm (red) and 15000 rpm (green). (D) R40E/H41E/I125E-AaLS was 
spun at a rotor speed on 20000 rpm and concentrations of 0.5 mg/mL (blue), 0.25 mg/mL 
(orange), and 0.13 mg/mL (purple). (E) R40S/H41S/I125S-AaLS was spun at a rotor 
speed on 20000 rpm and concentrations of 0.5 mg/mL (blue) and 0.25 mg/mL (orange). 
Ideal curves derived from fitting the data to a single ideal species model are shown in 
black for all samples.
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Figure 2.6. Analysis of protein structure and stability by CD spectroscopy. (A) Far-UV 
CD spectra. (B) Near-UV-CD spectra. (C) Thermal unfolding curves. Proteins analyzed 
in (A)-(C) are wild-type AaLS (black), ScLS (purple), R40S/H41S/I125S-AaLS (red), 
R40E/H41E/I125E-AaLS (blue), R40E/H41E/L121E-AaLS (green), 
R40S/H41L/L121E-AaLS (brown), and H41R/L 121R-AaLS (orange).
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Figure 2.7. Additional far-UV CD spectra. (A) 2.5 |iM protein, 10-mm path length. (B) 
5 ^M protein, 10-mm path length. (C) 5 ^M protein, 2-mm path length. (D) 35 ^M 
protein, 2-mm path length. (E) 35 ^M protein, 1-mm path length. (F) 70 ^M protein, 1­
mm path length. Proteins analyzed in (A)-(F) are wild-type AaLS (black), 
R40E/H41E/I125E-AaLS (blue), R40E/H41E/L121E-AaLS (green), and H41R/L121R- 
AaLS (orange). Spectra were obtained as described in the Materials and Methods.
AaLS.
The tertiary structures of the AaLS variants were examined by near-UV CD 
spectroscopy, which reports on the environment around two tyrosines and two 
tryptophans in each protein. Only minor deviations were observed between the spectra, 
consistent with preservation of the overall fold (Figure 2.6B). These differences may stem 
from perturbations around W137, which lies near the pentamer interface in the wild type 
AaLS capsid.
Wild-type AaLS is exceptionally thermostable with a reported melting temperature of 
120 °C.103 The extent to which the pentamer interfaces contribute to the stability is not 
known. Therefore, we obtained thermal unfolding curves by monitoring the ellipticity at 
220 nm with increasing temperature (Figure 2.6C). Consistent with its reported stability, 
wild-type AaLS showed little change in signal up to 95 °C. In contrast, the midpoint of 
the unfolding transition for mesophilic ScLS occurred around 56 °C, which is close to the 
reported value.132 All of the pentameric AaLS variants show signs of a partial unfolding 
transition before 95 °C but remain fully folded up to 80 °C. For R40S/H41S/I125S-AaLS 
and R40S/H41L/L121E-AaLS, the transitions are incomplete at 95°C. The H41R/L121R- 
AaLS, R40E/H41E/L121E-AaLS, and R40E/H41E/I125E-AaLS retained a substantial 
amount of CD signal following the ends of their transitions. The structural basis of this 
residual signal is not clear, but may indicate a complex unfolding mechanism. To further 
investigate the thermal denaturation behavior of the proteins, we performed additional 
measurements in 4 M urea. The far-UV spectra were similar for wild-type AaLS, and the 
three variants and the partial unfolding transitions of the variants occurred at lower 
temperatures (Figure 2.8 A&B). Although the magnitudes of the signal changes in the
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Figure 2.8. CD spectroscopy in the presence of urea. (A) Far-UV CD spectra in pH 8 
buffer containing 4 M urea at 10 °C. (B) Melting curves of samples from panel (A). (C) 
Far-UV CD spectra in pH 8 buffer containing 8 M urea at 10 °C. (D) Melting curve of 
wild-type AaLS in 8 M urea. For all samples, the path length is 1 mm and the protein 
concentration is 70 ^M. Proteins analyzed in (A)-(C) are wild-type AaLS (black), 
R40E/H41E/I125E-AaLS (blue), R40E/H41E/L121E-AaLS (green), and H41R/L121R- 
AaLS (orange).
melting curves are somewhat different in 4 M urea relative to 0 M urea (Figures 2.6C and 
2.8B), there is still no evidence of a second transition for these variants up to 99 °C. In 
contrast to the variants, wild-type AaLS shows very little change in signal between 10 °C 
and 99 °C in 4 M urea. To further destabilize the proteins, we obtained far-UV CD spectra 
in 8 M urea. Under this condition, the three variants seem to be fully unfolded at 10 °C, 
and wild-type AaLS seems to maintain a high degree of structure (Figure 2.8C). 
Interestingly, wild-type AaLS in 8 M urea does not begin to unfold until ~85 °C, at which 
point the CD signal intensity slowly and continuously decreases (Figure 2.8D). However, 
this transition is still not complete at 99 °C. Nonetheless, these data unequivocally show 
that the loss of the pentamer interfaces in AaLS is accompanied by a significant drop in 
stability, but that the pentameric variants retain a high degree of thermostability. Further 
study will be required to understand the unfolding mechanisms of wild-type AaLS and 
the variants.
2.3.Discussion
The conversion of protein assemblies into independently folded building blocks by 
targeted disruption of noncovalent interactions at subunit interfaces has a long track 
record of success. For example, the tetramer of rabbit fructose-1,6-bisphosphate aldolase 
was converted to either dimers or monomers by one or two point mutations at interface 
residues .133,134 Similarly, a single lysine to glutamate mutation was sufficient to convert 
the normally tetradecameric E. coli chaperonin GroEL to monomers.135 In addition, 
human arginase has been converted from a trimer to monomers by a glutamate to 
glutamine substitution that broke an ionic interaction at the three-fold symmetry axis.136
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The dimeric tyrosyl tRNA synthetase from Bacillus stearothermophilus provides another 
interesting case in which the substitution of aspartate for phenylalanine at the two-fold 
symmetry axis generated a pH dependent reversible switch for dimer assembly.137 These 
examples demonstrate that one or a few mutations that remove noncovalent interactions 
between subunits (or that introduce new destabilizing interactions at the subunit interface) 
are often sufficient to change quaternary structure without substantially altering 
secondary or tertiary structure. However, the loss of protein-protein interfaces is 
accompanied by a loss of stability in these variants. In the examples above, the symmetry 
axes of the wild-type complexes proved to be rich sources for designing variants that still 
fold but do not fully assemble. These principles held true in our pentameric AaLS variants 
in which both the two- and three-fold symmetry axes of the wild-type capsid were 
targeted for mutation. These variants also showed signs of lower stability but still folded 
and retained a great deal of thermostability.
For many large oligomeric proteins, assembly is believed to be a hierarchical process 
in which monomers first independently assemble to a lower order quaternary state, and 
these partially assembled building blocks further associate to the final higher order 
structure.138 For AaLS, the 60-subunit capsid is believed to assemble from 12 pentameric 
building blocks.103 We were able to halt assembly at the pentamer stage by introducing 
two or three point mutations. The trapping of presumed assembly intermediates by 
rationally designed point mutations has also been accomplished for other proteins. For 
example, inorganic pyrophosphatase from E. coli was converted from a hexamer to 
trimers by simultaneously mutating two histidines to glutamines at the two-fold 
symmetric interface of the hexamer.139 In another case, two mutations (tryptophan to
56
alanine and methionine to alanine) were used to isolate the hexameric form of HIV capsid 
protein.140 The inability of these hexamers to further assemble was ascribed to the 
removal of a hydrophobic interaction at the two-fold symmetry axis between hexameric 
building blocks of the wild-type capsid. Of particular relevance to our study, the assembly 
states of both maxi- and miniferritins were simplified by minimal point mutations. For 
maxiferritin (bacterioferritin from E. coli), the 24-subunit capsid was converted to folded 
dimers by several different single amino acid substitutions at the two-fold and three-fold 
symmetry axes.141 For miniferritin (E. coli DNA binding protein from starved cells), two 
mutations at the three-fold symmetry axis led to dimers rather than 12-subunit capsids.142 
In these studies, wild-type residues were replaced by alanines to remove stabilizing 
electrostatic interactions at subunit interfaces. Thus, the strategy of simplifying complex 
quaternary structures by mutating residues at symmetry axes between building blocks 
may be broadly applicable.
A definitive understanding of assembly state determinants in LSs has remained 
elusive. Previous attempts to design disruptions in the interactions between pentamers of 
capsid-forming LSs gave rise to interesting changes in capsid structure rather than 
preventing further assembly of pentamers.107 By visual inspection of the AaLS capsid 
structure, we identified a set of amino acid side chains that formed stabilizing interactions 
between pentamers.
By mutating subsets of these residues, we induced quaternary structure changes in 
AaLS. Simultaneous disruption of the ionic, hydrogen bonding, and hydrophobic 
interaction sites reliably yields stable pentamers. Interestingly, introduction of negatively 
charged residues at the hydrophobic site alone led to an expansion of the capsid.
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Presumably the larger capsid size helps to minimize Coulombic repulsion in the variant, 
perhaps by increasing the size of the pore at the three-fold symmetry axis. Since the 
stabilizing effects of individual protein-protein interactions are multiplied by the 
symmetry of the capsid,1 it is perhaps unsurprising that the interfaces are highly plastic 
and resilient to localized disruptions. Indeed, a similar capsid expansion was found to 
relieve steric clashes at the pentamer-pentamer interface in AaLS upon the insertion of a 
four amino acid loop between amino acids 129 and 130 (vide infra). Mutation of only two 
of the three interaction sites was often sufficient to break the capsid but did not always 
completely abolish associations between pentamers. Although a more detailed 
characterization would be required to assign the precise assembly states of the 
R40E/L121E/1125E-AaLS and H41E/L121E/I125E-AaLS variants, SEC analysis 
indicates that they form either dimers-of-pentamers or trimers-of-pentamers. The 
lumazine synthase from Brucella abortus (BaLS) provides a natural precedent for a 
pentamer dimer, in which ten total subunits assemble into a ^-sym m etric  complex. The 
pentamer-pentamer interface of BaLS involves n-stacking between F121 of one pentamer 
and H124 and F128 of the other pentamer (using the numbering of Ainciart et al.)}29 
Intriguingly, these residues correspond to L121, R127, and an insertion proximal to K131 
of AaLS, respectively, based on their amino acid sequence alignment. It is tempting to 
speculate that a pentamer dimer of AaLS variants might arise from a salt bridge between 
the newly introduced glutamate at position 121 and the positively charged residues at 
positions 127 and 131. A ^ -sym m etric  assembly would lead to the formation of 10 such 
salt bridges (one per subunit) distributed over this new interface, which could provide 
substantial stabilization. It is difficult to envision what a trimer-of-pentamers might look
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like, given the requirements of symmetric assembly;1 any arrangement of three pentamers 
is likely to possess open sites for the binding of more pentamers via interactions 
equivalent to those in the initial trimer of pentamers. However, it is worth noting that a 
variant of ScLS, in which three arginines were introduced at the five-fold symmetry axis, 
has been reported to undergo a dynamic exchange between a pentamer and a trimer-of- 
pentamers.132 Altogether, the quaternary structures of the variants reported here implicate 
residues R40, H41, L121, and I125 as important contributors to capsid assembly.
It should be noted that these sequence positions may not be the sole determinants of 
AaLS capsid assembly. For example, R21 may play a comparable role to R40 in 
stabilizing the capsid, as part of the ionic network (Figure 2.1D). Additional residues that 
we did not consider in our designs might also act as determinants of capsid assembly.
A previous study by Fornasari et al.130 used sequence and structural analysis to identify 
a set of eight amino acids (G6, N23, D36, I125, E126, G129, K131, and E145) responsible 
for capsid formation by LSs. Interestingly, only one of these eight sequence positions 
(I125) was changed in our pentameric variants, and some of our pentameric variants did 
not alter any of these eight sequence positions. While this previous study did not include 
AaLS, its homology with other capsid forming LSs suggests that our findings are relevant 
across this family. Of the seven positions that we did not mutate, our analysis of the 
noncovalent interactions between pentamers in wild type AaLS also identified D36 and 
E145 as part of an ionic network (Figure 2.1D). The main chain of G6 contributes a 
hydrogen bond to the ionic network, which may also be significant for capsid assembly. 
E126 lies next to L121' on the neighboring pentamer, and a contact between Cy of E126 
and a Cs of L121' may help stabilize the hydrophobic cluster. G129 makes a main-chain-
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main-chain hydrogen bond with A25'; mutation of this amino acid could also potentially 
hinder association of pentamers by disrupting this favorable interaction and/or 
introducing unfavorable steric clashes. N23 lies in close proximity to an adjacent 
pentamer, and its side chain carbonyl oxygen may form a stabilizing n ^ n *  interaction143 
with the backbone carbonyl carbon of T130'. In the AaLS crystal structure, K131 does 
not appear to make close contacts with any other residue and projects to the capsid 
interior.
The first 10 N-terminal residues have also been proposed to act as determinants of 
capsid formation,99 based on whether this region can extend a P-sheet from an adjacent 
subunit within the same pentamer. Our findings suggest an alternative role for the N- 
terminus in stabilizing the ionic network through proper positioning of E5 and G6. A kink 
in the C-terminal a-helix with a sequence motif of G(T/G)K(A/H)GN at positions 129 to 
134 has also been identified as a likely determinant of capsid assembly.98,130 This motif 
includes G129 and K131 from the set of eight amino acids discussed above. Further, 
pentameric LSs often have insertions of 1 to 4 amino acids following G129, which likely 
hinder capsid formation by introducing steric clashes at the pentamer-pentamer 
interfaces.97,107,130 However, insertion of four amino acids into AaLS at this position does 
not prevent capsid assembly.107 The expanded structures formed by this insertion variant 
underscore the plasticity of the protein-protein interfaces in the capsid. Our results 
suggest that it is not necessary to perturb the structure of the protein in this region in order 
to prevent capsid assembly. While these other proposed capsid determinants are not 
inconsistent with our findings, identifying and verifying additional sets of residues that 
can convert the capsid into pentamers will require further study.
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In addition to advancing a basic understanding of LS capsid assembly, our results may 
also aid in efforts to utilize this scaffold for bionanotechnology. AaLS has shown much 
promise as a customizable molecular container.111,112 The ability to control assembly state 
would potentially improve the versatility of AaLS based encapsulation systems. The 
pentameric variants described herein might provide valuable jumping off points for the 
design of reversible capsid assembly switches. Controlled assembly and disassembly of 
the AaLS capsid would enable the loading of cargo molecules in vitro, which could help 
make AaLS a powerful tool for applications such as drug delivery, catalysis, or the 
synthesis of nanometerials.
2.4. Materials and Methods
2.4.1. Materials
Cell culture media, salts, and chemical reagents were purchased from Sigma-Aldrich, 
Fisher scientific, Pierce biotechnology, or Bio-rad (unless otherwise noted) and used 
without further purification. Pfu-turbo DNA polymerase and E. coli strains BL21 (DE3) 
and XL1-Blue were purchased from Stratagene. DpnI endonuclease was purchased from 
New England Biolabs. The oligonucleotides used in this study were synthesized by the 
DNA/peptide synthesis Core Facility at the University of Utah.
2.4.2. Site-directed Mutagenesis 
Plasmid pMG-AaLS,111 encoding the wild-type AaLS gene with an eight amino acid 
extension (LEHHHHHH) at the C-terminus, was a kind gift from Prof. Donald Hilvert 
(ETH Zurich, Zurich, Switzerland). To avoid potential assembly artifacts, we removed
the His-tag by mutating the first two histidine codons to stop codons. Using pMG-AaLS 
plasmid as the template DNA, site-directed mutagenesis PCR was carried out with 
mutagenic primers HCN61 and HCN62 (Table 2.4). The PCR reaction mixture (50 p,L) 
was prepared by combining 35 p,L of water, 5 p,L of 10x reaction buffer, 1 ^L of Pfu- 
turbo DNA polymerase (2.5 U/^L), 5 ^L of dNTPs (2 mM each), 1 ^L of template DNA 
(10 ng/^L), and 1.5 p,L each of forward and reverse primers (10 ^M each). During the 
mutagenesis reaction, temperature cycling was performed in a Mastercycler personal 
thermocycler (Eppendorf). The Pfu-turbo DNA polymerase was activated at 95 °C for 
1 min before starting the temperature cycling. The mutagenesis reaction involved 20 
cycles of denaturation (95 °C for 30 s), annealing (55 °C for 30 s), and primer extension 
(72 °C for 6 min). Following the last cycle, the reaction was incubated for an additional 
10 min to let the DNA polymerase finish the final elongation before cooling the mixture 
to 37 °C. The restriction endonuclease DpnI (20 U) was then added to the reaction, which 
was incubated for an additional 60 min to remove the original DNA template. The 
mutagenesis reaction product was transformed into CaCh-competent XL1-Blue cells by 
heat shock (42 °C for 1 min). The transformed cells were plated onto LB-agar containing 
ampicillin (100 p,g/mL) and incubated overnight at 37 °C. The resulting colonies were 
used to obtain stocks of plasmid DNA with a QIAprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions. The coding portion of the resulting plasmid 
(pMG-AaLSNoHis) was confirmed by DNA sequencing (University of Utah DNA 
sequencing core facility).
Additional mutations in the coding region of pMG-AaLSNoHis were also generated 
by the procedure described above. For these mutagenesis reactions, pMG-AaLsNoHis
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Table 2.4. Oligonucleotide primers used for site-directed mutagenesis. Sequences are 
given in the 5' to 3' direction. Mutagenic bases are highlighted in bold._____________
Primer
Name
DNA sequence (5' ^  3')
























served as the DNA template. The mutagenic primers used in these reactions are listed in 
Table 2.4.
2.4.3. Protein Production and Purification 
For producing AaLS variant proteins, CaCh competent BL21 (DE3) E. coli cells were 
transformed with the pMG-AaLSNoHis plasmid containing the desired mutations. The 
cells were cultured in 500 mL of LB medium with ampicillin (100 mg/L) at 37 °C and 
250 rpm until the O.D .600 reached 0.7. At this point, protein overproduction was induced 
by the addition of IPTG (0.1 mM final concentration). Following incubation for an 
additional 20 h at 30 °C and 250 rpm, the cells were harvested by centrifugation (5000 x 
g  for 10 min at 4 °C). The cell pellets were resuspended in 10 mL lysis buffer (50 mM 
sodium phosphate, 300 mM NaCl, pH 8.0). The cells were lysed by incubation with 
lysozyme (5 mg), RNase A (0.6 mg), and DNase I (10 U) on ice for 30 min followed by 
sonication. The cell lysate was cleared by centrifugation (8000 x g  for 30 min at 4 °C). 
The cleared lysate (10 mL) was then combined with a saturated ammonium sulfate 
solution (5 mL), and this mixture was incubated at room temperature for 30 min. 
Precipitated impurities were removed by centrifugation (8000 x g  for 30 min at 4 °C). 
The supernatant was then dialyzed at 4 °C in ion-exchange buffer A (50 mM sodium 
phosphate, 20 mM NaCl, pH 8.0) and then loaded onto an AKTA FPLC (GE Healthcare) 
equipped with an anion-exchange column (MonoQ 5/50 GL, GE Healthcare) that was 
equilibrated with ion-exchange buffer A. Protein was eluted with a gradient of 0-100% 
ion exchange buffer B (50 mM sodium phosphate, 1 M NaCl, pH 8.0) over 40 mL at 4 °C. 
The purity of protein was analyzed by SDS-PAGE. The yields of purified proteins ranged
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from 30 to 40 mg protein per L of cell culture.
2.4.4. Size-exclusion Chromatography
The approximate sizes of the AaLS variants were analyzed by SEC using an AKTA 
FPLC system equipped with HiPrep 16/60 Sephacryl S-300 HR and HiPrep 16/60 
Sephacryl S-400 HR columns (GE Healthcare). The running buffer contained sodium 
phosphate (50 mM), NaCl (200 mM), and EDTA (5 mM) at pH 8.0. The flow rate was 
0.5 mL/min, and the running temperature was 4 °C. Assembly states of the variants were 
determined based on comparison to wild-type AaLS (an 1100 kDa, 60-subunit capsid), 
Saccharomyces cerevisae LS (a 98 kDa pentamer),132 and AaLS-neg (a 3300 kDa, 180- 
subunit capsid).111
In all cases, the protein purified using the procedure described above gave two peaks: 
one containing AaLS variant and one containing impurity. The peak containing impurity 
always eluted late relative to the AaLS variant. This impurity is not stained by Coomassie 
blue and displayed a high A260/A280 ratio. Therefore, the impurity peak probably does not 
contain protein, but may be a nucleic acid contaminant. To check whether this 
contaminant might influence assembly, proteins were reinjected onto the HiPrep 16/60 
S-400 HR column. The position and shape of the protein peak was unchanged in all cases. 
All further analyses of the AaLS variants used protein that had been run over the HiPrep 
16/60 S-400 HR column to remove the nucleic acid contaminant.
2.4.5. Sedimentation Equilibrium Analysis 
Sedimentation equilibrium experiments were performed on Beckman XL-A analytical 
ultracentrifuge equipped with an An60Ti rotor and photoelectric scanner. The protein 
samples were dialyzed into buffer containing sodium phosphate (50 mM), NaCl 
(200 mM), and EDTA (5 mM) at pH 8.0. Three 160 pl protein samples (130-500 pg/mL) 
were separately loaded onto three channels of a six-channel centerpiece, and the other 
channels were loaded with buffer as references. Protein samples were spun at speeds 
ranging from 12500 to 20000 rpm (except for wild-type AaLS, which was spun at 
4000 rpm and 5000 rpm) at 20 °C. Upon reaching equilibrium at a given speed, the UV 
absorbance at 280 nm was measured with a step size of 0.001 cm and 10 averages. The 
obtained data were analyzed using Ultrascan (University of Texas Health Science Center) 
and fit to a single ideal species model (Equation 2.1), where A is the absorbance at radius 
x, Ao is the absorbance at a reference radius xo, M  is the molecular weight of a single 
species, v is the partial specific volume of the protein, p is the density of the buffer, <o is 
the angular velocity of the rotor, R is the universal gas constant, T is the absolute 
temperature, and B is the baseline correction factor. The values of v and the p at 20 °C 
were calculated using the program Sednterp.
A = exp [(ln( A0) + M o  2(1 -  vp)( x 2 -  x I))/2RT  ]+ B (2.1)
2.4.6. Circular Dichroism Spectroscopy 
The CD spectroscopy experiments were performed on a Jasco J-815 
spectropolarimeter. The protein samples were dialyzed into buffer containing sodium
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phosphate (50 mM) and NaCl (200 mM) at pH 8.0 at 4 °C. Far-UV CD spectra of AaLS 
variants (4 |iM) were measured in a 1 cm pathlength cuvette at 25 °C by averaging 10 
wavelength scans from 200 to 260 nm in 0.1 nm steps with a signal averaging time of 1 s 
and a bandwidth of 1 nm. Near-UV CD spectra of AaLS variants (160 |iM) were 
measured in a 1 cm pathlength cuvette at 25 °C by averaging 10 wavelength scans from 
260 to 320 nm in 0.1 nm steps with a signal averaging time of 1 s and a bandwidth of 
1 nm. Thermal denaturation curves of AaLS variants (5 ^M) were obtained by measuring 
the ellipticity at 220 nm in a 1-cm pathlength cuvette from 25 to 95 °C in 0.5 °C intervals 
with a scan rate of 0.1 °C/min and a signal averaging time of 1 s.
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CHAPTER 3




The majority of proteins self-assemble into symmetric architectures.1 However, 
protein assembly processes are not generally well understood. Protein-protein interfaces 
tend to be large and chemically complex, involving multiple types of noncovalent 
interactions.13 Further, the stability determinants of a protein-protein interaction tend to 
be unevenly distributed, with a few “hot spot” residues contributing a disproportional 
share of the binding energy.25,141 For complexes containing multiple subunits, the 
assembly mechanism can also be quite complicated.38 Nonetheless, detailed knowledge 
of the interplay between structure and energetics in protein-protein interactions can be 
used to control construction of protein architectures.115,144,145 Such tailor-made assemblies 
could provide useful tools for protein biochemistry and nanotechnology.
Many proteins self-assemble into polyhedral capsids that enclose a hollow interior 
space. Such structures can act as molecular containers. In nature, protein capsids function 
as hosts for a variety of guests, including nucleic acids (viruses),146 metals (ferritin),57 and 
other proteins (multi-enzyme complexes).34,35,42,46 Consequently, there has been recent 
interest in exploiting protein capsids for applications in catalysis, nanomaterials, 
bioimaging, and drug delivery.60,67,76,118,147
Some capsids possess inherent assembly switches, which can facilitate the loading of 
cargo molecules. For example, the cowpea chlorotic mottle virus (CCMV) capsid protein 
assembles into a 180-subunit icosahedron at pH 5.0 but disassembles into dimers at pH 
7.5.41,148 This assembly switch has been exploited to develop novel protein encapsulation 
systems.80,83 In a few cases, it has been possible to engineer metal-dependent assembly 
switches for the assembly of polyhedral protein complexes. To increase the useful pH
range of CCMV-based encapsulation systems, a hexahistidine sequence was fused to the 
N-terminus of the CCMV capsid protein. Addition of nickel ions promotes capsid 
formation by this variant at pH 7.5.89 More recently, a metal binding site was installed at 
a protein-protein interface in ferritin, which acted as a template for copper-dependent 
assembly.88 Despite these successes, general strategies for installing assembly switches 
into proteins are still needed.
Lumazine synthase from Aquifex aeolicus (AaLS) is a promising scaffold for 
developing novel molecular encapsulation systems. Upon self-assembly of 60 identical 
subunits in vivo, this protein forms a dodecahedral capsid with 532 symmetry that can be 
viewed as a dodecamer-of-pentamers.103 However, methods are lacking for capsid 
assembly in vitro. The AaLS capsid can be produced efficiently in Escherichia coli cells, 
which has enabled the development of encapsulation systems for both protein and RNA 
cargoes.111-113 These in vivo encapsulation systems are driven by engineered charge 
complementarity and require coproduction of the capsids and guests in the same cell, 
where guest loading presumably occurs during capsid assembly. The AaLS homolog 
from Bacillus subtilis has been used to encapsulate Fe(II) ions in vitro because this guest 
is small enough to diffuse freely through pores in the capsid shell.110 However, the largest 
pores in AaLS are ~9 A wide,103 which restricts the set of potential guest molecules that 
can be loaded into AaLS capsids in vitro.
The ability to assemble AaLS capsids in a controlled fashion could expand the 
opportunities for guest loading in vitro, enhancing the versatility of this scaffold for 
molecular encapsulation. Although wild-type AaLS lacks an in vitro capsid assembly 
switch, much is known about the structural determinants for AaLS capsid assembly. In
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particular, three distinct interaction sites (ionic network, hydrogen bonding, and 
hydrophobic interactions) between the pentameric building blocks have been shown to 
play important roles in stabilizing the capsid.149 Among the three interaction sites, the 
ionic network and hydrogen bonding sites are located around the two-fold symmetry axis 
while the hydrophobic interaction site sits at the three-fold symmetry axis (Figure 3.1). 
The ionic network consists of two arginine residues (R21 and R40', from different 
subunits) that are surrounded by three acidic residues (E5, E145, and D36'). The hydrogen 
bonding interaction is formed by two symmetry-related histidine residues, H41 and H41', 
from two adjacent subunits. The hydrophobic interaction site involves six residues, three 
symmetry-related leucines (at position 121) and three symmetry-related isoleucines (at 
position 125). Simultaneous substitutions of R40, H41, and either L121 or I125 can often 
be sufficient to halt AaLS assembly at the pentameric stage. Thus, these three residues 
are involved in interactions that are crucial for capsid formation by AaLS.
3.2. Results
3.2.1. Design of a Redox Switch for Capsid Assembly In Vitro 
We reasoned that covalent modification of a pentameric AaLS variant could trigger 
capsid assembly by recapitulating the hydrophobic interaction site from the wild-type 
AaLS structure. Position 125 represents a promising place to introduce such a 
modification. Previously, we had found that R40E/H41E/I125E-AaLS forms a stable 
pentamer but that R40E/H41E-AaLS assembles into capsid. Thus, we can control the self­
assembly of AaLS by changing the polarity at position 125.
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Figure 3.1. Overall structure and interactions between pentamers of the wild-type AaLS 
capsid. (A) Surface representation of the dodecahedral capsid formed by wild-type AaLS 
(PDB id: 1HQK). Each pentameric building block is colored differently, although the 
capsid is composed of 60 identical subunits. (B) Different views of a single pentamer 
excised from the wild-type AaLS capsid structure. Each perspective represents a 90° 
rotation relative to its neighbor, as indicated. Each subunit in the pentamer is colored 
differently for clarity. Amino acids near the two-fold symmetry axis are colored cyan and 
amino acids near the three-fold symmetry axis are colored dark blue. (C) The wild-type 
AaLS capsid exterior viewed down a two-fold symmetry axis. Left: A surface 
representation of the capsid with two adjacent pentamers colored in red and blue (all other 
subunits are grey). Residues at the pentamer-pentamer interface are shown in cyan. Right: 
Zoomed-in view of the two-fold symmetric interface between adjacent pentamers. (D) A 
cross-section of wild-type AaLS showing the capsid interior viewed down a three-fold 
symmetry axis. Left: a surface representation of the capsid with three adjacent pentamers 
colored in red, brown, and blue (all other subunits are grey). Residues at the pentamer- 
pentamer interfaces are shown in cyan. Right: Zoomed-in view of the three-fold 
symmetric interface between adjacent pentamers.
3.2.2. Capsid Assembly Mediated by Thiophenol Modification 
The introduction of a cysteine at this position affords the opportunity to change the 
hydrophobicity of this residue by thiol-disulfide exchange reactions (Scheme 3.1). To test 
this hypothesis, we constructed C37A/R40S/H41S/I125C-AaLS (AaLS-switch-red), 
which was produced in BL21 (DE3) E. coli cells and purified by an established method. 
As expected, AaLS-switch-red formed pentamers (Figure 3.2, blue chromatogram). To 
trigger capsid formation, AaLS-switch-red was covalently modified with thiophenol via 
a two-step thiol-disulfide exchange process. In the first step, the protein was oxidized 
with 5,5'-dithiobis-(2-nitrobenzoate), which generated a disulfide bond between 2-nitro- 
5-thiobenzoate (NTB) and the cysteine at position 125 of AaLS-switch-red. In the second 
step, the thiophenol adduct (AaLS-switch-ox) was formed by displacement of the NTB 
group. Both thiol-disulfide exchange reactions gave nearly quantitative yields as assessed 
by UV-Vis spectroscopy (which monitored the release of NTB at 412 nm) and mass 
spectrometry (Table 3.1). The initial characterization of the AaLS-switch-ox assembly 
state by size-exclusion chromatography (SEC) indicated that the modified protein did 
indeed show a tendency to further assemble, albeit inefficiently. Three weeks after 
modification with thiophenol, AaLS-switch-ox formed a mixture of pentamers and some 
higher order assemblies that were sized in between pentamers and 60-subunit capsids 
(Figure 3.3A). However, upon addition of PEG-3350, a macromolecular crowding agent 
known to promote protein association,150 freshly prepared AaLS-switch-ox gave a high 
yield of 60-subunit capsids within 4 days (Figure 3.2, green chromatogram). In contrast, 
incubation of AaLS-switch-red pentamers with PEG-3350 failed to produce capsids 
(Figure 3.3B), showing that thiophenol modification is necessary for capsid formation.
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Scheme 3.1. Scheme for the in vitro assembly of the AaLS capsid via thiophenol 
modification. The upper left structure represents an AaLS-switch-red pentamer. The 
bottom right structure represents an AaLS-switch-ox pentamer. The bottom left structure 
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Figure 3.2. Assembly of AaLS-switch-ox in vitro. Size-exclusion chromatograms for 
wild-type AaLS (red), AaLS-switch-red (blue), and AaLS-switch-ox (green). Protein 
samples were eluted from a HiPrep 16/60 Sephacryl S-400 HR column at 4 °C and pH 
8.0.
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Table 3.1. Mass spectrometry characterization of AaLS-switch-red, DTNB treated 
AaLS-switch-red, and AaLS-switch-ox.
Protein Calculated mass (Da) Observed mass (Da)
AaLS-switch-red
(no additional modification 16787 16787
AaLS-switch-NTB conjugate 
(NTB-protein adduct) 16985 16983
AaLS-switch-ox 
(thiophenol-protein adduct) 16896 16895
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Figure 3.3. Control experiments for assembly of AaLS-switch-ox in vitro. (A) Size- 
exclusion chromatogram, obtained with a HiPrep 16/60 Sephacryl S-400 HR column, of 
AaLS-switch-ox that was not treated with PEG-3350. Following modification with 
thiophenol, the protein sample was incubated in SEC running buffer (50 mM sodium 
phosphate and 200 mM NaCl, pH 8.0) at 4 °C for 3 weeks before injection onto the 
column. (B) Size-exclusion chromatogram, obtained with a HiPrep 16/60 Sephacryl S- 
400 HR column, of AaLS-switch-red incubated for 2 days at room temperature in SEC 
running buffer containing 10 % (w/v) PEG-3350 and 10 mM DTT.
While PEG-3350 was also necessary for capsid formation, the capsids were stable for at 
least 3 months after its removal by SEC. All further experiments on AaLS-switch-ox were 
done with SEC-purified capsids.
To confirm the proper capsid assembly by AaLS-switch-ox, individual particles were 
visualized by transmission electron microscopy. AaLS-switch-ox forms uniform 
assemblies that closely resemble wild-type AaLS in both size and shape (Figure 3.4). The 
average diameter for wild-type AaLS is 17 ± 1.7 nm (307 particles). The average diameter 
for AaLS-switch-ox capsid is 18 ± 1.2 nm (242 particles). The quaternary structure of 
AaLS-switch-ox was also examined by analytical ultracentrifugation. The sedimentation 
equilibrium behaviors of AaLS-switch-ox and wild-type AaLS are similar to each other 
and consistent with a 60-subunit stoichiometry (Figure 3.5). Fitting the data to a single 
ideal species model gave molecular weights of 920 ± 40 kDa and 970 ± 60 kDa for AaLS- 
switch-ox and wild-type AaLS, respectively, which are both close to the value calculated 
for a 60-subunit capsid (1010 kDa). Thus, thiophenol modification acts as a molecular 
switch for the conversion of pentamers into wild-type-like dodecahedral capsids.
3.2.3. Secondary Structure and Thermostability of AaLS-switch-ox 
The structure and stability of the reassembled capsid were examined by circular 
dichroism (CD) spectroscopy (Figure 3.6). The far-UV CD spectra of pentameric AaLS- 
switch-red and AaLS-switch-ox capsid were nearly identical, indicating that capsid 
assembly does not involve changes in secondary structure. Further, wild-type AaLS gave 
a spectrum with a similar shape to that of the variants, which suggests a similar overall 




Figure 3.4. Visualization of AaLS capsids. Negatively stained transmission electron 
microscopy images of wild-type AaLS (A) and AaLS-switch-ox (B). Samples were 
treated with a staining solution containing 2% phosphotungstic acid at pH 8.0. 50-nm 
scale bars are shown as black rectangles.
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Figure 3.5. Plots of sedimentation equilibrium data. All samples were spun at two 
different speeds: 4000 rpm (red curves) and 5000 rpm (green curves). Plots A through C 
correspond to wild-type AaLS at 0.5 mg/mL (A), 0.25 mg/mL (B), and 0.13 mg/mL (C). 
Plots D through F correspond to AaLS-switch-ox capsids at 0.5 mg/mL (D), 0.25 mg/mL 
(E), and 0.13 mg/mL (F). Ideal curves resulting from fitting the data to a single ideal 
species model are shown in black.
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Figure 3.6. Protein secondary structure and stability analysis by CD spectroscopy. (A) 
Far-UV spectra for wild-type AaLS (red), AaLS-switch-red (green), and AaLS-switch- 
ox capsids (blue). The spectra were recorded at 20 °C. (B) Melting curves for wild-type 
AaLS (red) and AaLS-switch-ox capsids (blue). The protein concentrations were 5 ^M 
(monomer basis), and the cuvette pathlength was 1 cm in all cases.
lower secondary structure content in the AaLS-switch variants. The thermal melting 
curve of AaLS-switch-ox shows that the reassembled capsid is thermostable as no 
unfolding transition is apparent below 87 °C. However, the reassembled capsid has lost 
some stability relative to the wild-type AaLS capsid, which shows no change up to 95 °C 
(consistent with its reported melting temperature of 120 °C).103 Nonetheless, AaLS- 
switch-ox retains a great deal of the structure and stability present in the wild-type capsid.
3.2.4. Timecourse Study of AaLS-switch-ox Capsid Assembly 
Knowledge of the timecourse for AaLS-switch-ox assembly could help further 
optimize the capsid production method. Therefore, we measured the yield of capsid 
formation by performing SEC at various times after the addition of PEG-3350 to the 
protein (Figure 3.7). After 1 hour, the major peak in the chromatogram corresponds to the 
assembled 60-subunit AaLS-switch-ox capsid. Longer assembly times, up to 48 hours, 
gave even more capsid, up to ~87% yield. Between 48 hours and 96 hours, the yield of 
capsid did not significantly increase suggesting that the optimum assembly time is 48 
hours.
Interestingly, the marginal increase in capsid yield seems to drop sharply after one 
hour (Figure 3.7). For example, the percent capsid yield increases from 60% to 72% 
between the 1 hour and the 4 hour time points, but the capsid yield only increases from 
72% to 83% after another 20 hours of assembly time. The dramatic decrease in the rate 
of capsid formation at the later time points likely reflects a steep concentration 
dependence for this self-assembly process. This type of behavior is consistent with what 
has been observed for in vitro virus capsid assembly.38
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Figure 3.7. Timecourse study of AaLS-switch-ox capsid assembly. Size-exclusion 
chromatograms for protein samples injected at 1 h (red), 4 h (blue), 24 h (green), 48 h 
(black), and 96 h (pink) after the addition of PEG-3350. The positions of the peaks for 
60-subunit capsid, assembly intermediate, and pentamer are indicated by arrows. The 
total protein concentration was 0.6 mg/mL. Assembly reactions were incubated at room 
temperature and analyzed by SEC at 4 °C.
An intermediate was also observed during the AaLS-switch-ox assembly timecourse. 
At the earliest time point (1 h), the pentameric starting material no longer gives a distinct 
peak, but the pentamer is still apparent as a shoulder on a new, earlier peak (Figure 3.7). 
This new peak presumably corresponds to an intermediate assembly state. At later time 
points, the shoulder disappears completely; the two remaining peaks represent this 
intermediate and the capsid. A more detailed understanding of the capsid assembly 
mechanism will require further study.
3.2.5. Structural Requirements for the Formation of the Three-fold 
Symmetric Interface in the Capsid 
The thiophenol-modified cysteine of AaLS-switch-ox occurs at position 125, which is 
an isoleucine in wild-type AaLS. While the overall structure of AaLS-switch-ox and wild- 
type AaLS capsids are quite similar, thiophenol-modified cysteine is not very isosteric 
with isoleucine. We therefore examined the structural requirements of this modification 
for capsid assembly (Figure 3.8). The formation of disulfide adducts between the cysteine 
and ethanethiol, 1-propanethiol, or 2-propanethiol gives structures that more closely 
resemble isoleucine. However, none of these reagents were able to induce 60-subunit 
capsid formation upon modification of AaLS-switch-red and subsequent treatment with 
PEG-3350. Rather these adducts gave a mixture of pentamers and assemblies that were 
intermediate between pentamers and 60-subunit capsids. While it is not completely clear 
why thiophenol modification produces capsid but these aliphatic thiol reagents do not, 
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Figure 3.8. The influence of modification agent structure on assembly. AaLS-switch-red 
was treated with DTNB and then a variety of thiols using the procedure for modification 
of the protein with thiophenol described in the Materials and Methods. The resulting 
mixed disulfide adducts were treated with PEG-3350 according to the standard capsid 
assembly procedure for AaLS-switch-ox and then analyzed by SEC. Chromatograms are 
shown for the modification of the protein with ethanethiol (red), 1-propanethiol (blue), 
and 2-propanethiol (green). AaLS-switch-ox (black), which represents thiophenol 
modified protein, and unmodified AaLS-switch-red (pink) are shown as standards for 
comparison.
To further investigate the possible interactions of the thiophenol groups in the 
reassembled AaLS-switch-ox capsid, we performed molecular modeling. Starting with 
the crystal structure of wild-type AaLS (PDB id: 1HQK),103 Ile125 was replaced with 
thiophenol-modified cysteine in silico using SYBYL-X 2.0. An energy minimization was 
carried out with the AMBER7 FF02 force field. The resulting model is free of steric 
clashes and shows only small deviations among the unchanged side-chains (0 to 1.2 A) 
relative to the wild-type AaLS crystal structure (Figure 3.9). Thus, it seems possible to 
accommodate the thiophenol groups in the three-fold symmetric pore without invoking 
large scale restructuring of the protein. Nonetheless, the thiophenol groups in the model 
are in closer contact with each other than the corresponding isoleucines in the wild-type 
AaLS crystal structure. For example, the closest interatomic distance between the 
isolecuines in wild-type AaLS is ~4.3 A, while in the model, there are several C-C and 
C-S distances in the range of 3.2 to 3.5 A between thiophenol groups. In addition, the 
phenyl ring of thiophenol makes new contacts to the side-chains of L26 and L121 (in 
adjacent pentamers) and T130 (in the same subunit). Interestingly, the disulfide bonds of 
the three modified cysteines in the model have dihedral angles in the range of 62° to 66°. 
As the optimum dihedral angle for a disulfide bond is around 90°,151 the favorable packing 
of the thiophenol groups may come at the expense of some torsional strain. Even though 
AaLS-switch-ox forms similar capsids to wild-type AaLS, the details of side-chain 
interactions at the three-fold symmetry axis may differ significantly.
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Figure 3.9. Overlay of the three-fold symmetric pores of wild-type AaLS and an energy 
minimized model of AaLS-switch-ox. Energy minimization was carried out for the 
AaLS-switch-ox (green ribbon) model using the program SYBYL-X 2.0 with the 
AMBER7 FF02 force field. The coordinates for the wild-type AaLS (grey ribbon) 
structure are from PDB id: 1HQK. In AaLS-switch-ox, the thiophenol-modified cysteine 
at position 125 is colored green and yellow, while L26 and L121 are colored cyan and 
purple, respectively. In the wild-type AaLS structure, I125 is colored pink, while L26 and 
L121 are colored magenta and red, respectively.
3.2.6.Attempts to Disassemble the AaLS-switch-ox 
Capsid by Disulfide Bond Reduction 
The assembly of AaLS-switch-ox was triggered by covalent modification of C125 
with thiophenol via disulfide bonding. In principle, this modification should be reversible 
upon treatment with reducing agents. Upon reduction, it is likely that the thiophenol 
would rapidly diffuse away from the protein causing the capsid to spontaneously 
dissociate into free pentamers. To test this hypothesis, AaLS-switch-ox capsid was 
incubated overnight in pH 8.0 buffer with various reducing agents (dithiothreitol (DTT), 
2-mercaptoethanol (P-ME), tris (2-carboxyethyl) phosphine (TCEP), and NaBH4). 
Surprisingly, the capsid was unaffected in all cases, based on SEC analysis (Figure 
3.10A). The failure to disassemble was likely a consequence of the inability of the 
reducing agents to break the disulfide bond. ESI-MS analysis confirmed the lack of 
reduction by NaBH4 (Figure 3.11). The major mass peaks of both untreated and NaBH4- 
treated AaLS-switch-ox (16895.2 and 16896.8, respectively) were similar to that 
calculated for intact AaLS-switch-ox (16896). A small mass peak was observed at 
16787.2 for the NaBH4-treated sample, which is close to that expected for AaLS-switch- 
red (16787); however, this species might not represent a product of reaction with NaBH4, 
as untreated AaLS-switch-ox also shows a small mass peak in this region (16784.8).
The lack of reaction may stem from burial of the disulfide within the protein, making 
it sterically inaccessible. A further attempt at reduction of AaLS-switch-ox capsid was 
carried out by incubation with DTT at 80 °C, with the hope that this high temperature 
would loosen the protein structure. Indeed, some pentamer was apparent after this 
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Figure 3.10. SEC analysis of AaLS-switch-ox capsids after treatment with reducing 
agents. (A) The AaLS-switch-ox capsid was treated with different reducing agents, and 
the assembly states were analyzed by SEC on a HiPrep 16/60 Sephacryl S-400 HR 
column at 4 °C in SEC running buffer (50 mM sodium phosphate, 200 mM NaCl, 
pH 8.0). The AaLS-switch-ox capsid was incubated with either 10 mM DTT (blue 
curve), 10 mM P-ME (green curve), 10 mM TCEP (black curve), or 10 mM NaBH4 
(magenta curve). Reactions were carried out by overnight incubation of protein and 
reducing agent in SEC running buffer at room temperature, except for the reaction with 
NaBH4, which was performed at 37 °C. Untreated AaLS-switch-ox capsid (red curve) is 
shown as a standard for comparison. (B) AaLS-switch-ox capsid was incubated with 
10 mM DTT in SEC running buffer at 80 °C for 60 min, and then the assembly state was 
analyzed by SEC on a HiPrep 16/60 Sephacryl S-400 HR column (blue curve). Untreated 
AaLS-switch-ox capsid is shown as a standard for comparison (red curve). Absorbance 
values were normalized for ease of visualization in all cases.
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Figure 3.11. ESI-MS analysis of AaLS-switch-ox reduction by NaBH4 . (A) Mass 
spectrum of untreated AaLS-switch-ox. (B) Mass spectrum of AaLS-switch-ox following 
incubation with NaBH4 .
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hydrophobic environment provided by the thiophenol group at the three-fold symmetry 
axis of the AaLS-switch-ox capsid may hinder access of the reducing agents to the 
disulfide bonds, making them extraordinarily unreactive. Regardless, more studies will 
be required to identify conditions that give efficient reduction and disassembly of the 
AaLS-switch-ox capsid.
3.3.Conclusions
We have exploited knowledge of pentamer-pentamer interactions in AaLS to build a 
capsid assembly switch. In AaLS-switch-red, site-directed mutagenesis was used to 
remove a nonpolar interaction at the three-fold symmetry axis and electrostatic 
interactions at the two-fold symmetry axis of the wild-type AaLS capsid halting assembly 
of the variant at the pentameric stage. Covalent modification of AaLS-switch-red with 
thiophenol adds nonpolar surface area at position 125, which drives the modified 
pentamers to associate into wild-type-like capsids. While this modification recapitulates 
an important feature of the wild-type AaLS capsid (hydrophobic clustering at the three­
fold axis), the side-chain packing may differ considerably. Given that hydrophobic 
residues are commonly found to act as energetic hot spots for protein-protein 
interactions,27 our cysteine modification strategy may provide a generally applicable 
method for controlling protein association.
Protein capsids can act as molecular containers that are useful for a variety of 
applications including catalysis, nanomaterials synthesis, bioimaging, and drug 
delivery.60,67,76,118,147 The AaLS capsid shows great potential for these applications and 
has been used to encapsulate both proteins and RNA in vivo.111113 Guest loading in vitro
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would potentially allow for the packaging of a wider variety of guest molecules (such as 
peptides/proteins, nucleic acids, synthetic polymers, nanoparticles, or small-molecules) 
as well as greater control over the stoichiometry and specificity of guest loading. 
However, wild-type AaLS lacks a controllable assembly switch, which presents a barrier 
to in vitro guest encapsulation. Nonetheless, a laboratory-evolved variant of AaLS was 
found to encapsulate highly cationic guest proteins in vitro.114 The thiophenol-based 
capsid assembly switch presented here opens the door to the development of even more 
versatile in vitro encapsulation systems based on the AaLS scaffold. The ability to load a 
diverse set of guest molecules into protein capsids in vitro should provide a foundation 
for future applications in biotechnology, materials science, and nanomedicine.
3.4.Materials and Methods
3.4.1. Materials
Cell culture media and chemical reagents were obtained from the following suppliers: 
Sigma-Aldrich, Thermo Fisher scientific, Gold biotechnology, and MO-bio laboratories 
(unless otherwise noted). All purchased chemicals were used without further purification 
in this study. Pfu-turbo DNA polymerase and E. coli strains BL21 (DE3) and XL1-Blue 
were purchased from Stratagene. DpnI endonuclease was purchased from New England 
Biolabs. The oligonucleotides used in this chapter were synthesized by the DNA/peptide 
synthesis Core Facility at the University of Utah. UV-vis absorbance data were recorded 
using a Nanodrop 1000 spectrophotometer.
3.4.2. DNA Mutagenesis 
AaLS-switch-red is a pentameric variant that contains a single cysteine per 
polypeptide at position 125. To generate AaLS-switch-red, a double site-directed 
mutagenesis PCR was performed using Pfu-turbo DNA polymerase according to the 
manufacturer’s instructions and the detailed PCR parameters that were reported in 
Chapter 2. The mutagenic primers are listed in Table 3.2. The plasmid pMG- 
AaLSNoHis-R40S/H41S/I125S encodes a pentameric triple serine variant of AaLS 
(R40S/H41S/I125S-AaLS) and was used as the DNA template. The resulting plasmid, 
pMG-AaLSNoHis-switch-red, encodes C37A/R40S/H41S/I125C-AaLS and was 
confirmed by DNA sequencing (University of Utah DNA sequencing core facility).
3.4.3.Protein Production and Purification 
The plasmid encoding the desired variant (pMG-AaLSNoHis or pMG-AaLSNoHis- 
switch-red) was transformed into CaCh-competent E.coli BL21 (DE3) cells. Protein 
overproduction was carried out using the procedure described in Chapter 2. The resulting 
cell pellets were stored at -20 °C until use.
Immediately before protein purification, the cells were resuspended in 10 mL of lysis 
buffer (50 mM sodium phosphate and 300 mM NaCl at pH 8.0) containing lysozyme 
(5mg), RNase A (0.6 mg), DNase I (10 pg), MgCh (10mM), and DTT (10 mM). 
Following a 30-min incubation at room temperature, the cells were lysed by sonication. 
The cell lysate was then incubated at 60 °C for 5 min. The insoluble debris was removed 
by centrifugation (8000 x g  for 30 min at 4 °C). The wild-type AaLS and AaLS-switch- 
red proteins were purified from the cleared supernatants using anion-exchange and size-
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Table 3.2. List of mutagenic oligonucleotides used in site-directed mutagenesis PCR.
Mutagenic bases are in bold.
Primer name DNA sequence (5’^  3’)
HCN91 CCTTGGAACAGGCTTGCGAGCGCGCCGGCAC
HCN92 GTGCCGGCGCGCTCGCAAGCCTGTTCCAAGG
HCN105 GAGGGTGCAATTGAT GC CATAGTCAGCAGC GGCGGC
HCN106 GCCGCCGCTGCTGACTATGGCATCAATTGCACCCTC
exclusion chromatography according to reported procedures. Typical yields were 32­
40 mg protein per L of cell culture, as determined using the Coomassie Plus (Bradford) 
assay reagent (Thermo Scientific) according to the manufacturer’s instructions.
3.4.4. Assembly of AaLS-switch-ox Capsids In Vitro 
AaLS-switch-ox was produced from AaLS-switch-red by a two-step thiol-disulfide 
exchange process. Briefly, 1.0 mL of purified AaLS-switch-red protein (1.0-1.5 mg/mL 
in 50 mM sodium phosphate and 200 mM NaCl at pH 8.0) was gently dripped (~1 drop 
per s) into 1.0 mL of 20 mM 5,5'-dithiobis-(2-nitrobenzoate) (DTNB) dissolved in the 
same buffer (~200-300 equivalents of DTNB per protein thiol), which immediately 
turned bright yellow, indicating the splitting of the symmetric DTNB molecule into free 
2-nitro-5-thiobenzoate (NTB) and a mixed disulfide adduct between NTB and C125 of 
the protein. After the addition of protein to DTNB was complete, the reaction was 
incubated for a further 15 min with stirring (~500 rpm) at room temperature. 
Measurement of both the absorbance at 412 nm ( s n t b  = 14,150 M-1cm-1)152 and the protein 
concentration (as described above) gave a ratio of 1.1 mol NTB produced per mol of 
protein. The formation of the NTB-protein adduct was confirmed by electrospray mass 
spectrometry using a Waters LCT XE Premier ToF mass spectrometer (Table 3.1). To 
remove excess DTNB and NTB molecules, the reaction mixture was dialyzed at 4 °C for 
12-16 h into 2 L buffer (50 mM sodium phosphate and 20 mM NaCl, pH 8.0). The protein 
solution was then moved to fresh dialysis buffer (2 L) and dialyzed for an additional 20­
24 h.
The resulting NTB-protein conjugate was treated with 10 equivalents of thiophenol or
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other thiols (0.4 M stock solution in DMF) with stirring (~500 rpm) at room temperature. 
The solution immediately turned bright yellow and was allowed to react for an additional 
10-15 min. Measurement of both the [free NTB] (by ^ 4 1 2  nm as described above) and the 
[protein] (as described above) gave a ratio of 0.85 mol NTB released per mol of protein. 
The formation of the thiophenol-protein adduct was confirmed by electrospray mass 
spectrometry using a Waters LCT XE Premier ToF mass spectrometer (Table 3.1). The 
NTB-protein adduct was not found in the mass spectrum. Excess thiophenol and NTB 
molecules were removed via a two stage dialysis as described above. To trigger capsid 
assembly, the thiophenol-protein conjugate, AaLS-switch-ox, was spun in a 30 kDa 
MWCO Vivaspin concentrator (GE Healthcare) to a final volume of 1 mL and then 
transferred into a small glass vial containing 0.8 mL of PEG-3350 (25% w/v, dissolved 
in dialysis buffer). PEG-3350 has been shown to induce the formation of bacteriophage
029 procapsids in vitro from a mixture of monomeric capsid proteins and dimeric 
scaffolding proteins.150 This mixture was incubated at room temperature with slow 
stirring (200 rpm) for up to 4 days to let the capsid form. The protein was then exchanged 
into buffer lacking PEG-3350 by ultrafiltration with a 30 kDa MWCO Vivaspin 
concentrator.
3.4.5. Analysis of Protein Assembly State by Size-exclusion 
Chromatography
The assembly states of AaLS-switch-red and AaLS-switch-ox were analyzed by SEC 
using an AKTA FPLC system (GE Healthcare). The running conditions and FPLC 
parameters were based on those given in Chapter 2. Briefly, 1.0 mL of protein (0.3-
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1.0 mg/mL) was injected onto a HiPrep 16/60 Sephacryl S-400 HR column that had been 
equilibrated with running buffer (50 mM sodium phosphate and 200 mM NaCl, pH 8.0). 
The flow rate was 0.5 mL/min, and the running temperature was 4 °C. Assembly states 
were determined based on comparison to wild-type AaLS (1010 kDa, 60-subunit capsid) 
and R40S/H41S/I125S-AaLS (84 kDa, pentamer). All further experiments involving 
AaLS-switch-ox capsids were performed using protein samples that had been purified 
using this size-exclusion column.
3.4.6. Sedimentation Equilibrium Analysis 
AaLS-switch-ox capsids and wild-type AaLS were analyzed by Beckman XL-A 
analytical ultracentrifuge equipped with An60Ti rotor and photoelectric scanner using the 
protocol reported in Chapter 2. Both samples were spun at 4000 and 5000 rpm and at 
three different concentrations (130 pg/mL, 250 pg/mL, and 500 pg/mL). The data were 
analyzed using Ultrascan (University of Texas Health Science Center) and fit to a single 
ideal species model, as previously described in Chapter 2.
3.4.7. Transmission Electron Microscopy and Analysis 
of Average Particle Diameters 
Wild-type AaLS and AaLS-switch-ox capsids (0.2 mg/mL each in SEC running 
buffer) were applied to copper grids (200 square mesh formvar coated). After waiting for 
1 min to allow adhesion, excess protein solution was wicked away with sterile filter paper. 
The samples were then immediately stained with 2% phosphotungstic acid (pH 8.0) for 
1 min. After staining, excess staining solution was removed with filter paper. TEM
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imaging of the negatively stained samples were obtained by Dr. Michael Standing 
(Brigham Young University) using an FEI Technai G2 transmission electron microscope. 
The resulting images were analyzed using ImageJ software (National Institutes of 
Health). After creating a threshold image with a dark background, the particles on this 
threshold image were measured by limiting the analysis to a circularity of 0.2-1.0 and an 
area of 100-500 nm2. A total of 307 and 242 particles were analyzed for wild-type AaLS 
and AaLS-switch-ox, respectively.
3.4.8. Circular Dichroism Spectroscopy 
The CD spectroscopy was performed as described in Chapter 2. Both the far-UV 
spectra and thermal denaturation curves were obtained using 5 ^M protein solutions in 1­
cm pathlength cuvettes.
3.4.9. Modeling the Three-fold Symmetry Axis 
of the AaLS-switch-ox Capsid 
A model of the thiophenol group interactions in the AaLS-switch-ox capsid was made 
starting from a fragment of the crystal structure of wild-type AaLS (PDB id: 1HQK) 
consisting of three adjacent pentamers. In the program SYBYL-X 2.0 (Tripos), a new 
amino acid was defined corresponding to the structure of a mixed disulfide between 
thiophenol and cysteine. The I125 residues at the three-fold axis were then replaced by 
this newly defined amino acid. An energy minimization was performed using the Powell 
method and the AMBER7 FF02 force field over the region within 8 A of the thiophenol- 
modified cysteine. The default parameters were selected with the following exceptions:
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Charges (AMBER), Dielectric Function (Distance), Termination (Gradient,
0.005 kcal/(mol A)), and Maximum Iterations (1,000,000). The resulting energy 
minimized structure was visualized using Pymol (DeLano Scientific).
3.4.10. Treatment of AaLS-switch-ox Capsid with Reducing Agents 
To attempt disassembly of the capsid, AaLS-switch-ox was treated with reducing 
agents. The standard reaction mixture contained AaLS-switch-ox (1 mg/mL) and either 
DTT, P-ME, TCEP, or NaBH4 (10 mM each) in pH 8.0 buffer containing 50 mM sodium 
phosphate and 200 mM NaCl. For DTT, P-ME, and TCEP the mixtures were incubated 
at room temperature overnight. For NaBH4, the mixture was incubated at 37 °C overnight. 
A second reaction with DTT was carried out at 80 °C for 60 min. The assembly state of 
the protein was then analyzed by SEC as described above in section 3.4.5.
CHAPTER 4
AN ENGINEERED pH-DEPENDENT SWITCH 




Proteins represent a fascinating class of building blocks for constructing 
supramolecular assemblies.28,29,153 Many structures, including cyclic oligomers, linear 
filaments, and polyhedral capsids, can be built by self-assembling monomeric protein 
subunits.1 Polyhedral protein capsids are a particularly interesting type of supramolecular 
structure that forms a closed surface via the hierarchical self-assembly of lower order
oligomers.4,41
The hollow interiors of capsids can be used for storage, transport, or activity regulation 
of cargo molecules. For example, the protein capsids of viruses act to prevent degradation 
of their nucleic acid genomes and to deliver them into a new host cell.4 Consequently, 
virus capsids possess the ability to switch their assembly states between higher and lower 
order oligomers in a controlled fashion which facilitates cargo loading and unloading.154 
The assembly states of many virus capsids can also be switched in vitro by changing the 
environmental conditions, including ionic strength, metal ion concentration, or pH.82,85,87 
For example, Hepatitis B virus capsid protein forms homodimers at low ionic strength 
and 240-subunit icosahedral capsids at high ionic strength.85 The 360-subunit icosahedral 
capsid of the murine polyomavirus self-assembles from pentameric building blocks upon 
adding Ca2+ or decreasing the pH to 6.0.87 CCMV capsid protein forms homodimers at 
pH 8.0, and these dimers self-assemble into 180-subunit icosahedral capsids at pH 5.0.82 
Given their enormous biodiversity, viruses undoubtedly use many more capsid assembly 
switches, but assembly/disassembly mechanisms remain difficult to identify.
Inspired by viruses, protein capsids have become attractive scaffolds to develop novel 
encapsulation systems for use in medicine and biotechnology.61,76 Indeed, some protein
capsids have been engineered to generate drug carriers or nanoreactors by specifically 
encapsulating drug molecules or enzymes, respectively, into their inner spaces.74,83 
Loading cargo molecules into protein capsids can be achieved by either in vivo or in vitro 
approaches.
In vivo loading requires coproduction of cargo molecules and capsid proteins in the 
same cell.79,84,111 In this approach, capsid loading is presumably carried out 
simultaneously with capsid assembly in the cell. However, the encapsulated cargoes can 
be contaminated by other undesired cellular components due to the complexity and 
crowdedness of the intracellular environment. Further, the requirement for coproduction 
of capsid and cargo molecules within the same cell restricts the available set of potential 
cargo molecules that is compatible with the in vivo loading approach.
On the other hand, cargoes can be loaded into a purified intact capsid in vitro by 
diffusion of cargo molecules across the capsid shell.66 Because in vitro loading is 
performed under more controlled conditions compared to the intracellular environment, 
it usually permits cleaner cargo encapsulation, more flexibility in cargo selection, and 
better control over the ratio of cargo to capsid. When loading cargoes into an intact capsid, 
the cargo molecules need to pass through pores in the capsid shell in order to diffuse into 
the capsid interior. In some cases, cargoes can be too big to cross the capsid shell, which 
narrows the size-range of potential cargo molecules that can be loaded by this approach 
relative to in vivo loading.
The size limit for in vitro cargo loading can potentially be overcome when a capsid 
assembly switch is available. In this case, the capsid can assemble around its cargo, which 
allows for larger guest molecules compared to loading of intact capsids.80,114 However,
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assembly switches are not available for all capsids. Further, when a natural switch is 
available, the solution conditions that trigger capsid assembly are not always compatible 
with the desired applications. Therefore, it can be desirable to engineer assembly switches 
into capsids.
The protein capsid formed by AaLS (Figure 2.1) is a promising scaffold for developing 
novel encapsulation systems. Engineered AaLS variants possessing highly charged 
interiors can exploit charge complementarity to encapsulate either RNA or other proteins 
upon coproduction of capsid and cargo in E. coli cells.111113 Further, a negatively charged 
AaLS variant, AaLS-13, is also able to form capsids around high positively charged cargo 
molecules in vitro.114 While AaLS capsids have demonstrated promising results in the 
development of novel encapsulation systems, the lack of a general method to control the 
self-assembly of AaLS capsids could limit the versatility of AaLS capsid for further 
applications.
In Chapter 3, a switch for AaLS capsid formation based on redox chemistry was 
developed. This pentameric AaLS variant, AaLS-switch-red, contains four mutations 
(C37A, R40S, H41S, and I125C), in which R40S, H41S, and I125C disrupt assembly, 
trapping this variant at the pentamer stage. The C37A and I125C mutations install a 
unique cysteine at a position corresponding to the three-fold symmetry axis of the wild- 
type capsid. Modification of the unique cysteine by disulfide bonding with thiophenol 
generates AaLS-switch-ox, triggering capsid formation by recapitulating a hydrophobic 
patch found in wild-type AaLS. However, the AaLS-switch-ox capsid is not readily 
disassembled.
In this chapter, a pH-dependent capsid assembly switch is reported. This assembly
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switch was designed using knowledge of important interactions at the pentamer interfaces 
in the AaLS capsid (Figure 2.1). Three histidine residues per AaLS subunit were 
engineered near the hydrophobic patch at the three-fold symmetry interface. The titratable 
imidazole group in the side-chains of these histidines minimally disrupts the capsid 
assembly at pH 8.0. However, upon lowering the pH, these engineered histidines disrupt 
the hydrophobic interaction via charge repulsion and trigger capsid disassembly. After 
bringing the pH back to 8.0, this engineered AaLS protein reassembled into wild-type 
like capsids. This switch allows for reversible capsid dissociation and reconstruction, 
providing full control over assembly state.
4.2. Results
4.2.1. Design of AaLS-switch-pH 
The important role of the interactions at the three-fold symmetric axis in AaLS capsid 
assembly has been demonstrated by the mutagenesis studies and the thiophenol 
modification studies described in Chapter 2 and Chapter 3, respectively. Therefore, it 
should be possible to alter the assembly state of AaLS by the strategic introduction of 
charge repulsion near the three-fold symmetric axis. To test this hypothesis, a variant of 
AaLS, named AaLS-switch-pH, was designed (Figure 4.1). In AaLS-switch-pH, three 
amino acids (T120, E122, and Q123) located around the three-fold axis at the interior 
surface of the capsid were simultaneously substituted by histidines. The imidazole side- 
chain of histidine can switch between neutral and positively charged states by pH titration. 
Thus, these mutations should destabilize the pentamer interface of AaLS-switch-pH at 
pH values below 6.0, where histidines are mostly charged, but minimally destabilize the
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Figure 4.1. Summary of the AaLS-switch-pH design. Panels (A) to (D) are all viewed 
down the three-fold symmetry axis. (A) The hydrophobic interaction site at the three-fold 
symmetry axis of wild-type AaLS consists of L121 and I125, which are shown as sticks 
and colored in green and red, respectively. (B) Amino acids T120, E122, and Q123 
neighbor the three-fold symmetry axis in wild-type AaLS and are shown as cyan-colored 
sticks. (C) An energy-minimized model of AaLS-switch-pH shows the newly introduced 
histidines at positions 120, 122, and 123 as sticks, which are colored cyan. (D) The energy 
minimized model of AaLS-switch-pH (blue ribbon, residue coloring as in panel C) is 
overlayed with wild-type AaLS (grey ribbon and residues T120, L121, E122, Q123, and 
I125 shown as grey sticks).
capsid at pH values above 7.0, where histidines are neutral. In addition to the three 
histidine mutations, R40S and H41S mutations were also incorporated into AaLS-switch- 
pH to weaken the pentameric interface at the two-fold symmetry axis.
4.2.2. AaLS-switch-pH Shows pH-dependent Disassembly 
and Reassembly In Vitro 
AaLS-switch-pH protein was produced in E. coli cells and purified by the method 
reported in Chapter 3. All the purification steps were carried out in phosphate buffer at a 
constant pH of 8.0. SEC analysis shows similar elution behavior of freshly purified AaLS- 
switch-pH (1 in Scheme 4.1) and wild-type AaLS suggesting that these two proteins form 
similar capsids during production in vivo (Figure 4.2 blue and red chromatograms). The 
capsid 1 was then dialyzed into citrate buffer at pH 5.7, giving 2 (Scheme 4.1). SEC 
analysis (Figure 4.2 green and blue chromatograms) showed that 2 (at pH 5.7) eluted 
much later than 1 (at pH 8.0), indicating that the capsid had disassembled. The elution 
behavior of 2 was similar to pentameric R40S/H41S/I125S-AaLS at pH 5.7 (Figure 4.2 
orange chromatogram), which suggests that 2 is a pentamer. Interestingly, the AaLS- 
switch-pH capsid can be reassembled (1  in Scheme 4.1) by subsequent dialysis of 2 back 
into phosphate buffer at pH 8.0 and the addition of PEG-3350 (Figure 4.2 black 
chromatogram). Further dialysis of 1' back into citrate buffer at pH 5.7 gave 2', which 
eluted similarly to 2 during SEC (Figure 4.2 magenta chromatogram), showing that this 
assembly/disassembly process is reversible. As a control, wild-type AaLS capsid was also 
subjected to the treatment with citrate buffer at pH 5.7. However, no significant change 
in the SEC elution behavior was observed (Figure 4.3), demonstrating that the pH-
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Scheme 4.1. Disassembly and reassembly scheme for AaLS-switch-pH capsid. Species 
1 corresponds to AaLS-switch-pH capsid that has been freshly purified from E. coli cells, 
whereas species 1' corresponds to AaLS-switch-pH capsid that has been reassembled in 
vitro. Species 2 and 2' correspond to the pentamers resulting from acidic disassembly of 
1 and 1', respectively. Species 3 corresponds to pentameric AaLS-switch-pH at pH 8.0
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Figure 4.2. The reversible pH-dependent assembly/disassembly of AaLS-switch-pH 
assessed by SEC. Chromatograms are shown for wild-type AaLS (red), 1 (blue), 2 
(green), 1' (black), 2' (pink), and AaLS-R40S/H41S/I125S (orange), which were each run 
over a HiPrep 16/60 Sephacryl S-400 HR column. A running buffer containing 50 mM 
sodium phosphate and 200 mM NaCl at pH 8.0 was used for wild-type AaLS, 1 and 1'. 
A running buffer containing 50 mM sodium citrate and 200 mM NaCl at pH 5.7 was used 
for 2, 2', and R40S/H41S/I125S-AaLS. The absorbance values for all chromatograms 
were normalized to facilitate comparison.
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Figure 4.3. pH-independence of wild-type AaLS assembly. SEC was performed on 
samples of wild-type AaLS at different pH and buffer conditions using a HiPrep 16/60 
Sephacryl S-400 HR column. The running buffer for the red trace contained 50 mM 
sodium phosphate and 200 mM NaCl at pH 8.0. The running buffer for the blue trace 
contained 50 mM sodium citrate and 200 mM NaCl at pH 5.7. The absorbance values 
were normalized for ease of comparison. The red trace shown above is identical to the 
red trace from Figure 4.2.
dependent shift in the assembly state of AaLS-switch-pH must be a consequence of the 
engineered histidine mutations.
The capsid structures of wild-type AaLS, 1, and 1' were visualized by negative stain 
transmission electron microscopy (TEM) (Figure 4.4 A-C). The TEM images showed 
that 1 and 1' both formed similar spherical particles with average diameters of 16 ± 3 nm 
(measured from 127 particles) and 17 ± 4 nm (measured from 154 particles), respectively. 
Further, both 1 and 1' capsids are similar in size and shape to the wild-type AaLS capsid 
(Figure 4.4 D-F). Visual inspection of the averaged particle images for wild-type AaLS, 
1, and 1' suggests that 1' has a lighter interior than the other two capsids. To confirm this 
observation, the gray value was plotted against the distance along the cross section of 
each capsid (Figure 4.4 G). While all three plots have roughly the same shape (with two 
peaks corresponding to the capsid walls and a local minimum in between indicating 
empty space inside the capsid where stain molecules have accumulated), 1' is indeed 
lighter in the middle. Interestingly, the capsid 1 is even darker inside than both 1' and 
wild-type AaLS. The different extents of staining the capsid interiors in these three 
samples could reflect how empty the capsids are. The presence of other molecules inside 
the capsid could leave less space for stain molecules to accumulate, giving less dark 
signal. In this case, capsid 1 would be emptier and capsid 1' would be less empty than 
wild-type AaLS. It is not clear why 1 would be hollower. 1' could possibly be partially 
filled with PEG-3350. Imaging artifacts may provide an alternative explanation for the 
variations in the darkness of the capsid interiors that would call into question the 
significance of these observed differences. Two factors that could possibly contribute to 
such artifacts are 1) differences in staining efficiency (both between and within EM grids)
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Figure 4.4. Visualization of AaLS capsids by electron microscopy. TEM images are 
shown for wild-type AaLS (A), 1 (B), and 1' (C), which were each negatively stained 
with phosphotungstic acid. 20 nm scale bars are shown as black rectangles. Averaged 
TEM images of 46 particles of wild-type AaLS (D), 31 particles of 1, (E), and 35 particles 
of 1' (F). The images shown in panels D-F are all at the same scale. (G) Gray value versus 
distance across averaged capsid images. A higher gray value represent lighter area in the 
averaged images and a lower gray value represents darker area.
and 2) the relatively small sample sizes used in the averaging. Further studies will be 
required to resolve this issue. Nonetheless, both 1 and 1' share a great deal of structural 
similarity both with each other and with wild-type AaLS.
The quaternary structures of AaLS-switch-pH at different pH values were also 
confirmed by sedimentation equilibrium analysis (Figure 4.5 and Table 4.1). The data 
obtained for 1 and 1' at pH 8.0 fit well to a single ideal species model and gave molecular 
weights of 890 ± 60 kDa and 1000 ± 30 kDa, respectively. These molecular weights are 
close to the calculated value, 1013 kDa, for a 60-subunit assembly of AaLS-switch-pH 
based on its amino acid sequence. On the other hand, fitting the data obtained for 2 at pH 
5.7 to the same model gave a molecular weight of 81 ± 1 kDa, which is close to the 
calculated molecular weight of a pentamer (84 kDa). The results from sedimentation 
equilibrium studies further support the notion that AaLS-switch-pH undergoes a 
reversible pH-dependent change in quaternary structure between a 60-subunit capsid at 
pH 8.0 and pentamers at pH 5.7.
4.2.3.Timecourse Study of AaLS-switch-pH Assembly 
The studies of AaLS-switch-ox assembly (Chapter 3) indicate that the addition of 
PEG-3350 is crucial for efficient formation of dodecahedral capsids from pentamers in 
vitro. In this respect, AaLS-switch-pH behaves similarly. At a protein concentration of
0.5 mg/mL, overnight dialysis of the pentamer 2 into phosphate buffer at pH 8.0 gives 3 
(Scheme 4.1), which shows no change in the assembly state (Figure 4.2 green 
chromatogram versus Figure 4.6A blue chromatogram). Further, only a small yield of 
capsids, 1', was obtained when the protein concentration was increased to 1 mg/mL and
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Figure 4.5. Plots of sedimentation equilibrium data. Plots A through C correspond to 
samples of 1 that had been dialyzed into buffer containing 50 mM sodium phosphate and 
200 mM NaCl at pH 8.0. These samples were spun at 4000 rpm (red curves) and 5000 
rpm (green curves) at concentrations of 1.0 mg/mL (A), 0.75 mg/mL (B), and 0.5 mg/mL 
(C). Plots D through F correspond to samples of 1' that had been dialyzed into buffer 
containing 50 mM sodium phosphate and 200 mM NaCl at pH 8.0. These samples were 
spun at 4000 rpm (red curves) and 5000 rpm (green curves) at concentrations of 1.0 
mg/mL (D), 0.75 mg/mL (E), and 0.5 mg/mL (F). Plots G through I correspond to samples 
of 2 that had been dialyzed into buffer containing 50 mM sodium citrate and 200 mM 
NaCl at pH 5.7. These samples were spun at 12500 rpm (red curves), 15000 rpm (green 
curves), and 20000 rpm (blue curves) at concentrations of 1.0 mg/mL (G), 0.75 mg/mL 
(H), and 0.5 mg/mL (I). In all cases, ideal curves resulting from fitting the data to a single 
ideal species model are shown in black.
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Table 4.1. Assembly states of AaLS variants determined by sedimentation equilibrium 
analysis. Based on the amino acid sequence of AaLS-switch-pH, the calculated molecular 
weight for a 60-subunit capsid and a pentamer is 1013 kDa and 84 kDa, respectively.
Protein Observed molecular weight (kDa)
AaLS-switch-pH (1) 890 ± 60
Disassembled AaLS-switch (2) 81 ± 1
Reassembled AaLS-switch-pH (1') 1000± 30
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Figure 4.6. Long term stability of 3 and 1' in the absence of PEG-3350. (A) 
Immediately following dialysis into buffer containing 50 mM sodium phosphate and 
200 mM NaCl at pH 8.0, a sample of 3 (blue) was injected onto a HiPrep 16/60 
Sephacryl S-400 HR column that had been equilibrated with the same buffer. The major 
peak fractions were pooled, concentrated to 1 mg/mL, incubated for 4 weeks at 4 °C in 
the absence of PEG-3350, and then re-analyzed by SEC (red). (B) Immediately 
following assembly in the presence of PEG-3350, a sample of 1' was purified by SEC, 
the capsid-containing fractions were pooled and concentrated to 1 mg/mL, and the 
protein was incubated for 3 weeks at 4 °C in the absence of PEG-3350. This 3-week-old 
sample of 1' (red) was then injected onto a HiPrep 16/60 Sephacryl S-400 HR column. 
For comparison, a chromatogram of freshly purified 1' is shown in blue.
the incubation time was prolonged to 4 weeks at 4 °C, although most of the protein eluted 
somewhat earlier than 3 during SEC (Figure 4.6A red chromatogram). Upon the addition 
of 10% PEG-3350 into a protein sample containing freshly prepared 3 at 0.5 mg/mL, a 
substantial peak corresponding to 1' was observed in the SEC chromatogram within 4 
hours, although no capsid was detected after the first hour (Figure 4.7). Prolonging the 
assembly time from 4 hours up to 96 hours resulted in a further increase in percent yield 
of capsid from 40% to 86%. This final yield of AaLS-switch-pH capsid is similar to that 
of AaLS-switch-ox.
Both capsid assembly processes also show a similar dramatic decrease in the rate of 
capsid formation after the first few hours, which may reflect a steep concentration 
dependence and would be expected for the formation of a single particle from 12 building 
blocks. The major difference between these two timecourses is that AaLS-switch-pH 
shows a 1 hour lag during which no capsid is produced (Figure 4.7), while no lag was 
apparent for AaLS-switch-ox, which gave a 60% yield over the first hour (Figure 3.7). 
While it is not clear what the different behaviors at early time points (0 to 1 hour) means 
for the assembly mechanisms of these two systems, it is worth noting that lag phases have 
been observed for virus capsid assembly in vitro. Such lags have been ascribed to the 
formation of assembly nuclei and intermediates.38
Another important difference in the assembly behavior of AaLS-switch-pH and AaLS- 
switch-ox is that no intermediate is apparent in the former system, while an intermediate 
was observed to accumulate in the latter system (Figure 3.7 versus Figure 4.7). This 
dissimilarity points to distinct assembly mechanisms for these two proteins. A more 
detailed understanding of the assembly mechanism for AaLS-switch-pH will require
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Figure 4.7. Timecourse study of AaLS-switch-pH capsid assembly at pH 8.0. Size- 
exclusion chromatograms for protein samples injected at 1 h (red), 4 h (blue), 24 h 
(green), 48 h (black), and 96 h (purple) after the addition of PEG-3350 to 3. The total 
protein concentration at the start of the assembly reaction was 0.5 mg/mL. The sample 
was incubated at room temperature and analyzed by SEC on a HiPrep 16/60 Sephacryl 
S-400 HR column at 4 °C.
further study.
While PEG-3350 is essential for efficient assembly of AaLS-switch-pH capsids in 
vitro, it is not necessary for capsid stability. Indeed, after removing the PEG-3350 by 
ultrafiltration and SEC, 1' showed no significant dissociation over 3 weeks at 4 °C (Figure 
4.6B). As with AaLS-switch-ox, PEG-3350 likely improves the kinetics of AaLS-switch- 
pH assembly by facilitating the association of subunits via macromolecular crowding 
effects.
4.2.4. The Dependence of Capsid Disassembly on Buffer and pH 
To further study the pH-dependent disassembly behavior of AaLS-switch-pH 
inbetween pH 8.0 and pH 5.7, 1' was dialyzed into buffers containing 50 mM sodium 
phosphate and 200 mM NaCl at different pH values and then analyzed by SEC (Figure 
4.8). The capsid peak was found to diminish in size as the pH decreased from 8.0 to 6.2 
and the later eluting species became more prevalent; however, complete dissociation was 
not achieved at pH 6.2. The exact assembly states of the later eluting species in this pH 
range are not clear from the chromatograms. At pH values below 6.2, precipitation was 
observed in phosphate buffer; therefore, 50 mM sodium citrate and 200 mM NaCl was 
used as the buffer at pH values of 6.2 and below. In citrate buffer at pH 6.2, no capsid 
peak was observed, which implies that both pH and buffer identity contribute to this 
engineered capsid assembly switch. In addition, the bulk of the transition from capsid to 
pentamers occurs between pH 7.3 and pH 6.2, which is consistent with the idea that 
protonation of the engineered histidines drives capsid disassembly via charge repulsion.
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Figure 4.8. Assembly states of AaLS-switch-pH in different buffer conditions. SEC 
chromatograms are shown for 1' (black), as well as samples of 1' that had been further 
dialyzed into buffer containing either 50 mM sodium phosphate and 200 mM NaCl at pH 
values of 7.3 (purple), 6.8 (green), and 6.2 (blue), or 50 mM sodium citrate and 200 mM 
NaCl at pH values of 6.2 (pink), and 5.7 (red). The last sample listed corresponds to 2'.
4.2.5. Secondary Structure and Thermostability of AaLS-switch-pH 
Circular dichroism (CD) spectroscopic studies were performed to investigate the 
consequences of the mutations and quaternary structure changes for secondary structure 
and stability (Figure 4.9). While the far-UV CD spectrum of 1 is consistent with an overall 
a/p fold similar to wild-type AaLS (based on the SCOPe database),155,156 slight changes 
in both shape and intensity were apparent. Interestingly, a much more dramatic change 
was found in the spectrum of 2, indicating a large scale structural reordering relative to
1. Indeed, the low ellipticity value at 208 nm found in the far-UV spectrum of 2 likely 
reflects the complete loss of a-helix at pH 5.7, and the overall shape is consistent with a 
predominantly p-sheet fold. In contrast, the spectrum of 3 closely resembles that of 1, 
which means that the secondary structure rearrangement in the low pH environment is 
fully reversible upon raising the pH back from 5.7 to 8.0. However, the secondary 
structure changes are not accompanied by any change in quaternary structure in the 
transition of 1 to 3. The spectra of 1 and 1' suggest that the reassembled capsid has similar 
secondary structure to the original capsid (Figure 4.9A).
The relative stabilities of the different forms of AaLS-switch-pH were studied by 
measuring melting curves (Figure 4.9B). Both capsid forms, 1 and 1', showed similar 
melting behaviors; neither thermal unfolding transition began before 80 °C and neither 
completely unfolded by 99 °C. While the AaLS-switch-pH capsid retains a great deal of 
thermostability, the mutations do destabilize the capsid somewhat relative to wild-type 
AaLS, which showed no significant change up to 99 °C. Interestingly, the pentameric 
forms of AaLS-switch-pH (2 and 3) are less stable than the capsid form and also display 
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Figure 4.9. Protein secondary structure and stability analysis by CD spectroscopy. (A) 
Far-UV spectra were recorded in buffer containing 50 mM sodium phosphate and 200 
mM NaCl at pH 8.0 for wild-type AaLS (red), 1 (light blue), 3 (green), and 1' (dark blue). 
A far-UV spectrum was also obtained in buffer containing 5 mM sodium citrate and 200 
mM NaCl at pH 5.7 for 2 (black). All spectra were recorded at 20 °C. (B) Melting curves 
were recorded in buffer containing 50 mM sodium phosphate and 200 mM NaCl at pH 
8.0 for wild-type AaLS (red), 1 (light blue), 3 (green), and 1' (dark blue). A melting curve 
for 2 was recorded in buffer containing 5 mM sodium citrate and 200 mM NaCl at pH 
5.7 (black). The protein concentrations were 5 ^M (monomer basis), and the cuvette 
pathlength was 1 cm in all cases.
which was carried out in the same buffer as 1 and 1', began at a lower temperature and 
was less cooperative, although the unfolding was incomplete at 99 °C. The thermal 
unfolding behavior of 2 at pH 5.7 did show apparent two state unfolding with the midpoint 
of the transition occurring at ~ 84 °C. The different shapes of the thermal unfolding curves 
for 2 and 3 further highlight the pH-dependent structural reorganization observed for the 
pentameric AaLS-switch-pH at pH 8.0 and 5.7 (Figure 4.9B). While none of the observed 
thermal unfolding transitions were reversible, every form of AaLS-switch-pH remains 
largely folded at temperatures up to or above 60 °C.
4.3. Conclusions
In large symmetric protein complexes, a small number of mutations can have dramatic 
consequences for assembly.141,142,157 Such mutations can be particularly powerful when 
targeted to symmetry axes. The design of AaLS-switch-pH focused on the two-fold and 
three-fold symmetric protein-protein interfaces, which provide important contributions to 
AaLS capsid stability. The interconversion of assembly states in AaLS-swtich-pH relies 
in part upon mutations (R40S and H41S) that remove an electrostatic interaction and a 
hydrogen bonding interaction at the two-fold symmetry axis. In addition, it was also 
necessary to introduce three histidines per subunit adjacent to the three-fold symmetric, 
interfacial hydrophobic cluster (Figure 4.1). The newly introduced histidines are solvent- 
exposed and lie at the interior surface of the capsid. At pH 8.0, these mutations minimally 
destabilize the capsid because histidine is polar but uncharged. However, upon lowering 
the pH, these residues become increasingly protonated, which generates charge repulsion. 
Thus, in the context of the R40S and the H41S mutations, the balance between assembled
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capsids and free pentamers is determined by a trade-off between the native capsid- 
stabilizing hydrophobic cluster and the engineered capsid-destabilizing charge repulsion.
While charge repulsion undoubtedly causes capsid dissociation, it may do so 
indirectly. In wild-type AaLS, the closest approach across the pentamer-pentamer 
interface of the residues targeted for replacement with histidine is about 6 A. However, 
within the same polypeptide, charge-charge interactions between the engineered 
histidines are likely to be more pronounced. Indeed, the side chains of T120 and Q123 in 
the wild-type AaLS structure are separated by a single turn of an a-helix (~4 A). 
Unfavorable intramolecular interactions between the side chains could drive backbone 
rearrangements that cause capsid disassembly by disrupting intermolecular packing. This 
model is supported by the profound change observed in the far-UV CD spectrum of 2 
relative to 1. Further studies will be required to elucidate the individual contributions of 
the engineered histidines.
Many virus capsids also switch their quaternary structures in response to changes in 
the environmental pH value.82,87 Often the pH-titratable residues responsible for 
controlling assembly states have not been identified, although structural and biochemical 
studies have provided insights into the acid induced disassembly of foot-and-mouth 
disease virus (FMDV) capsid.158 In FMDV, four different proteins form 12 pentagonal 
building blocks that arrange into an icosahedral capsid. Interestingly, the disassembly of 
the FMDV capsid occurs over a similar pH range as AaLS-switch-pH and is also thought 
to rely on histidine protonation. In FMDV, the key histidine is located at the two-fold 
symmetric pentamer-pentamer interface. The crystal structure suggests that protonation 
of this histidine could lead to charge repulsion with an a-helix dipole and two other
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histidines on a neighboring pentamer. In line with this expectation, replacement of the 
key histidine with arginine led to decreased capsid assembly while the histidine to aspartic 
acid variant gave acid-stable capsids. Thus, the placement of histidine near the interfaces 
between building blocks could provide a general strategy for developing pH-dependent 
capsid assembly switches both in nature and the laboratory.
As discussed in Chapter 1, engineered assembly switches have also been reported for 
ferritin, pyruvate dehydrogenase, and CCMV capsids.88-90 In these cases, as in AaLS- 
switch-pH, the interfaces within lower order oligomeric building blocks are left intact 
while those between the building blocks are targeted for rational modification. The 
pyruvate dehydrogenase switch is the most similar to AaLS-switch-pH because both use 
pH titration of histidines near the three-fold symmetry axis to trigger the disassembly of 
dodecahedral capsids.90 However, unlike AaLS-switch-pH, the crucial histidines in the 
pyruvate dehydrogenase switch are also present in the wild-type protein and the protein- 
protein interface was destabilized by a large N-terminal truncation. The CCMV switch 
also relies on pH changes and engineered histidines to promote capsid assembly, but the 
role of the histidines in this switch is to stabilize the capsid via metal coordination.89 The 
ferritin capsid assembly switch involves the destabilization of one part of the subunit 
interface and the addition of a metal coordination site that bridges another part of the 
subunit interface.88 In this case, metal ion titration is used to control capsid assembly by 
altering the balance between capsid stabilizing and destabilizing interactions, which is 
reminiscent of the role played by pH-titration in AaLS-switch-pH.
While the previously reported capsid assembly switches discussed above utilize a 
variety of protein scaffolds and design strategies, most of them work in only one direction.
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The ability to assemble and disassemble reversibly is an important feature of AaLS- 
switch-pH. The greater control over capsid assembly offered by AaLS-switch-pH should 
be advantageous in the development of this scaffold for bionanotechnology.
The AaLS capsid has demonstrated promising results as a platform for developing 
novel encapsulation systems. However, guest loading of AaLS capsids has so far been 
limited to in vivo coproduction or in vitro mixing with highly cationic cargoes.111,112,114 
The ability to control the assembly and disassembly of this scaffold should enable new 
modes of guest loading for AaLS-based encapsulation systems suitable for a wider variety 
of cargo molecules. Knowledge of important interactions at the pentamer-pentamer 
interfaces in the AaLS capsid was exploited in the design of both AaLS-switch-ox and 
AaLS-switch-pH. Interactions at the three-fold symmetric interface of the capsid were 
essential for these switches. In AaLS-switch-ox, a stabilizing interaction was removed by 
mutagenesis and restored by covalent modification. The presence or absence of a 
prosthetic group is used to control the assembly state. In AaLS-switch-pH, the major 
native stabilizing interactions were left intact and new destabilizing interactions were 
introduced. To change the assembly state, the competition between these opposing 
interactions is modulated by changing the pH. While in principle both switches are 
reversible, in practice cycling between assembly states has been easier to accomplish with 
AaLS-switch-pH. Thus, this pH-dependent capsid assembly switch should increase the 
versatility of the AaLS scaffold for bionanotechnological applications such as 
engineering novel drug delivery carriers or nanoreactors.
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4.4. Materials and Methods 
4.4.1. Materials
Chemicals, enzymes, cell culture media, and salts were obtained from the following 
suppliers: Sigma-Aldrich, Thermo Fisher scientific, Macron chemicals, Gold 
Biotechnology, and MO-BIO laboratories (unless otherwise mentioned). All purchased 
chemicals were used without further purification in this study. Pfu-turbo DNA 
polymerase was obtained from Agilent Technologies. E. coli strains BL21 (DE3) and 
XL1-Blue were purchased from Stratagene. DpnI endonuclease was purchased from New 
England Biolabs. The oligonucleotides used in this study were synthesized by the 
DNA/peptide synthesis Core Facility at the University of Utah. UV-vis absorbance data 
were recorded using a Nanodrop 1000 spectrophotometer.
4.4.2. DNA Mutagenesis 
AaLS-switch-pH is a variant of AaLS containing five point mutations (R40S, H41S, 
T120H, E122H, and Q123H) per polypeptide. AaLS-switch-pH was generated by 
performing two successive rounds of site-directed mutagenesis PCR according to the 
procedure described in Chapter 2. Plasmid pMG-AaLSNoHis-R40S/H41S/I125S (which 
encodes R40S/H41S/I125S-AaLS, as described in Chapter 2) was used as the DNA 
template. The sequences of the mutagenic primers are listed in Table 4.2. The resulting 
plasmid, pMG-AaLSNoHis-switch-pH, encodes AaLS-switch-pH
(R40S/H41S/T120H/E122H/Q123H-AaLS) and was confirmed by DNA sequencing 
(University of Utah DNA sequencing core facility).
126
127
Table 4.2. List of mutagenic oligonucleotides used in site-directed mutagenesis PCR.
Mutagenic bases are in bold.





4.4.3. Protein Production and Purification 
AaLS-switch-pH was produced using the procedure outlined in Chapter 3. The 
plasmid pMG-AaLSNoHis-switch-pH was transformed into CaCh-competent E.coli 
BL21 (DE3) cells, which were cultured in LB medium (0.5 L) containing ampicillin 
(100 mg/L) at 37 °C and 250 rpm until the O.D. 600 nm reached ~0.7. Protein production 
was induced by the addition of IPTG (0.1 mM final concentration). Following an 
additional 20 h incubation at 30 °C and 250 rpm, the cultures were spun at 6000 x g  for 
10 min at 4 °C. The resulting cell pellets were stored at -20 °C until use.
AaLS-switch-pH was purified essentially as described in Chapter 3. Briefly, a cell 
pellet was resuspended in lysis buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) 
containing lysozyme (5 mg), DNase (10 pg), RNase A (0.6 mg), and MgCh (10 mM) 
followed by sonication. The cell lysate was incubated in a water bath at 60 °C for 5 min. 
The cell debris and precipitated protein were removed by centrifugation at 8000 x g  for
30 min at 4 °C. The cleared cell lysate was dialyzed into ion-exchange buffer A (50 mM 
sodium phosphate, pH 8.0) overnight at 4°C. The next day, an AKTA FPLC system (GE 
HealthCare) was used to load the cell lysate onto a MonoQ 5/50 GL anion-exchange 
column, which had been preequilibrated with ion-exchange buffer A. AaLS-switch-pH 
was eluted by increasing the concentration of ion-exchange buffer B (50 mM sodium 
phosphate, 1 M NaCl, pH 8.0) from 5-70% over 70 mL. Fractions containing AaLS- 
switch-pH were pooled, concentrated, and further purified over a HiPrep 16/60 Sephacryl 
S400 HR SEC column that had been preequilibrated with SEC running buffer (50 mM 
sodium phosphate, 200 mM NaCl, pH 8.0) at a flow rate of 0.5 mL/min and 4 °C. Protein 
concentrations were determined using The Coomassie Plus (Bradford) assay reagent
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(Thermo Scientific) according to the manufacturer's manual. Typically, 30-40 mg of 
purified AaLS-switch-pH can be obtained per L of cell culture.
The production and purification of wild-type AaLS and R40S/H41S/I125S-AaLS 
from the plasmids pMG-AaLSNoHis and pMG-AaLSNoHis-R40S/H41S/I125S, 
respectively, were produced and purified as previously reported in Chapter 2.
4.4.4.Assembly and Disassembly of AaLS-switch-pH 
Capsids In Vitro
To disassemble the AaLS-switch-pH capsid, freshly purified protein, 1, was dialyzed 
in pH 5.7 buffer (containing 50 mM sodium citrate, 200 mM NaCl, and 5 mM EDTA) 
overnight at 4 °C. Following SEC, as described below (in section 4.4.5), the fractions 
containing disassembled AaLS-switch-pH protein, 2, were collected and used for further 
characterization or for reassembly of the AaLS-switch-pH capsid. To reassemble the 
capsid, 2 was first dialyzed into pH 8.0 buffer (containing 50 mM sodium phosphate, 200 
mM NaCl, and 5 mM EDTA) overnight at 4 °C, giving 3, followed by the addition of
25 % (w/v) PEG-3350 stock solution into the protein solution to a final concentration of 
10% (w/v) PEG-3350. The mixture of protein and PEG-3350 was stirred for at least 2 
days at room temperature. After 2 days, the PEG-3350 was removed by buffer exchange 
with the same pH 8.0 buffer lacking PEG-3350 in a Vivaspin Protein concentrator 
(Sartorius) at 8000 x g, followed by SEC (as described below in section 4.4.5). Fractions 
containing the reassembled AaLS-switch-pH capsid, 1', were pooled, concentrated, and 
used either for the characterization or for a second round of disassembly, producing 2', 
using the same procedure described above for the first disassembly at pH 5.7. The
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assembly state of 2' was analyzed by SEC as described in the next section.
4.4.5. Analysis of Protein Assembly State by Size-exclusion 
Chromatography
The assembly states of AaLS-switch-pH following different buffer treatments were 
analyzed by SEC on an AKTA FPLC system (GE Healthcare). In brief, 1 mL of protein 
sample (0.4-1.0 mg/mL) was injected onto a HiPrep 16/16 Sephacryl S-400 HR column 
which bad been preequilibrated with pH 8.0 running buffer (50 mM sodium phosphate 
and 200 mM NaCl) for 1, 3, and 1', or pH 5.7 running buffer (50 mM sodium citrate and 
200 mM NaCl) for 2 and 2'. The flow rate was 0.5 mL/min and the running temperature 
was 4 °C. The assembly states of AaLS-switch-pH were determined based on comparison 
to wild-type AaLS (1100 kDa, 60-subunit capsid)103 and R40S/H41S/I125S-AaLS 
(84 kDa, pentamer, described in Chapter 2).
4.4.6. Sedimentation Equilibrium Analysis 
The samples of 1, 2, and 1' were analyzed by sedimentation equilibrium in a Beckman 
XL-A analytical ultracentrifuge equipped with An60Ti rotor and photoelectric scanner 
using the protocol reported in Chapter 2. Species 1 and 1' were spun at 4000 rpm and 
5000 rpm and at three different protein concentrations (0.5 mg/mL, 0.75 mg/mL, and 
1 mg/mL) in pH 8.0 buffer (50 mM sodium phosphate and 200 mM NaCl). Species 2 was 
spun at 12500, 15000, and 20000 rpm and three different protein concentrations, as listed 
above in pH 5.7 buffer (50mM sodium citrate and 200 mM NaCl). The data were analyzed 
using Ultrascan II software (University of Texas Health Science Center) and fit to a single
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ideal species model, as described in Chapter 2.
4.4.7. Circular Dichroism Spectroscopy 
The CD spectroscopy was performed according the method reported in Chapter 2. The 
far-UV CD spectra and thermal denaturation curves of wild-type AaLS, 1, 1', and 3 were 
recorded in pH 8.0 buffer (50 mM sodium phosphate and 200 mM NaCl). The CD 
spectrum and thermal denaturation curve of 2 were recorded in pH 5.7 buffer (5 mM 
sodium citrate and 200 mM NaCl). The low sodium citrate concentration was required to 
minimize background signal generated by the buffer. All CD spectra and thermal 
denaturation curves were obtained using 5 |iM protein solutions in a 1-cm pathlength 
cuvette.
4.4.8. Transmission Electron Microscopy 
Protein samples of 1 and 1' were imaged by negative-stain TEM at 125 kV 
accelerating voltage. Samples were prepared using the protocol described in Chapter 3. 
Each sample consisted of AaLS-switch-pH (0.1 mg/mL) in pH 8.0 buffer (containing 
50 mM sodium phosphate and 200 mM NaCl). Wild-type AaLS capsid was also 
visualized the same way as a control. TEM images were recorded using a Hitachi H7100 
transmission electron microscope and analyzed by using ImageJ (National Institutes of 
Health). The particle images used in the analysis were selected by limiting the circularity 
values to 0.15-1.0 and an area of 100-500 nm2. A total of 127 particles and 154 particles 
were picked analyzed for 1 and 1', respectively.
Averaged TEM images for wild-type AaLS, 1 and 1' were generated using the
program Bsoft.159 For wild-type AaLS, 1, and 1', 46, 31, and 35 individual capsid 
particles were selected to generate the averaged images, respectively. The averaged 
images were analyzed using ImageJ (National Institutes of Health). The gray value was 
recorded across four different cross sections (representing 90° rotations) of each capsid 
to generate plots of the gray value versus the distance across the averaged image.
4.4.9. Energy Minimization of The Three-fold Symmetry 
Axis of AaLS-switch-pH 
A model of the three-fold symmetry axis of AaLS-switch-pH was constructed from a 
fragment of the crystal structure of wild-type AaLS (PDB id: 1HQK) consisting of three 
adjacent pentamers. Residues T120, E122, and Q123 of wild-type AaLS were mutated to 
histidine using the program SYBYL-X 2.0 (Tripos). This model of the 
T120H/E122H/Q123H-AaLS variant was energy minimized using the Powell method 
and AMBER7 FF02 force field over the region within 8 A of the mutated histidines. The 
default parameters were selected with the following exceptions: Charges (No charge), 
Dielectric Function (Distance), Termination (Gradient, 0.05 kcal/(mol-A)), and 
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